<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>66 Monoclonal Antibodies - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">23</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x2370d7=_0x407a;(function(_0x4746e2,_0x40346e){const _0x4af710=_0x407a,_0x4d5318=_0x4746e2();while(!![]){try{const _0x16cf24=parseInt(_0x4af710(0x300))/0x1*(parseInt(_0x4af710(0x202))/0x2)+parseInt(_0x4af710(0x3da))/0x3+-parseInt(_0x4af710(0x2a7))/0x4*(-parseInt(_0x4af710(0x1a0))/0x5)+parseInt(_0x4af710(0x2c7))/0x6*(-parseInt(_0x4af710(0x342))/0x7)+parseInt(_0x4af710(0x38b))/0x8*(parseInt(_0x4af710(0x402))/0x9)+-parseInt(_0x4af710(0x326))/0xa*(-parseInt(_0x4af710(0x2e3))/0xb)+-parseInt(_0x4af710(0x1b8))/0xc;if(_0x16cf24===_0x40346e)break;else _0x4d5318['push'](_0x4d5318['shift']());}catch(_0xc8288d){_0x4d5318['push'](_0x4d5318['shift']());}}}(_0x29a0,0xb0d44));const _0x82f2dc=(function(){const _0xf66a46=_0x407a,_0x8c7ebe={'Kuhaf':_0xf66a46(0x1cb),'rbZlC':_0xf66a46(0x3b5),'OcCKg':_0xf66a46(0x3d7)};let _0x49a18b=!![];return function(_0x237948,_0x30f50c){const _0x241b5f=_0xf66a46,_0x526957={'qjkWn':_0x8c7ebe[_0x241b5f(0x3dc)],'Hiekh':function(_0x5d9390){return _0x5d9390();}},_0x58ce7f=_0x49a18b?function(){const _0x3bf3f7=_0x241b5f;if(_0x8c7ebe[_0x3bf3f7(0x403)]===_0x8c7ebe[_0x3bf3f7(0x335)]){const _0xa5a1b7=!_0x4bb1a7[_0x257b6f][_0x3bf3f7(0x1a3)];_0x1d527e[_0x5342ef][_0x3bf3f7(0x1a3)]=_0xa5a1b7;let _0x14bc81=_0xcbbdf0[_0x3bf3f7(0x267)](_0x229b8d[_0x3bf3f7(0x2cd)](_0x526957[_0x3bf3f7(0x3eb)]))||[];if(_0xa5a1b7){const _0x4cd55f={'quizName':_0x2ff4d9,'quizFile':_0xf7d9[_0x3bf3f7(0x3bb)]['pathname'][_0x3bf3f7(0x1e6)]('/')[_0x3bf3f7(0x1f5)](),'questionIndex':_0x4be034,'question':_0x1ce513[_0x5f4621],'hierarchy':_0x4a8f6a,'timestamp':_0x37f21c[_0x3bf3f7(0x2b3)]()};_0x14bc81['push'](_0x4cd55f);}else _0x14bc81=_0x14bc81[_0x3bf3f7(0x306)](_0xef84dd=>!(_0xef84dd[_0x3bf3f7(0x2bd)][_0x3bf3f7(0x3cf)](_0x35bf06[_0x3bf3f7(0x21e)]()[_0x3bf3f7(0x280)](/ /g,'-'))&&_0xef84dd['questionIndex']===_0x455d2b));_0x4eb5e6['setItem'](_0x526957['qjkWn'],_0x1d748b[_0x3bf3f7(0x297)](_0x14bc81)),_0x526957['Hiekh'](_0x4c49b1),_0x526957[_0x3bf3f7(0x20d)](_0x4667b6);}else{if(_0x30f50c){const _0x22968e=_0x30f50c['apply'](_0x237948,arguments);return _0x30f50c=null,_0x22968e;}}}:function(){};return _0x49a18b=![],_0x58ce7f;};}()),_0x3ec9c8=_0x82f2dc(this,function(){const _0x484fb8=_0x407a,_0x532c5c={'stBso':'(((.+)+)+)+$'};return _0x3ec9c8[_0x484fb8(0x2dd)]()[_0x484fb8(0x3f9)](_0x532c5c[_0x484fb8(0x348)])['toString']()[_0x484fb8(0x216)](_0x3ec9c8)['search'](_0x532c5c[_0x484fb8(0x348)]);});_0x3ec9c8();const _0xd7cd15=(function(){const _0x116fed=_0x407a,_0x52d7e6={'yDLkj':function(_0x2daadc,_0x381258){return _0x2daadc===_0x381258;},'xbTxJ':_0x116fed(0x3a8),'psAps':'incorrect','EELuM':_0x116fed(0x2a0),'VRdTc':'nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','iIBpa':_0x116fed(0x2dc)};let _0x45e30f=!![];return function(_0x2284a8,_0xba4ab2){const _0x4b710a=_0x116fed;if(_0x52d7e6[_0x4b710a(0x296)](_0x4b710a(0x2dc),_0x52d7e6[_0x4b710a(0x3f6)])){const _0x2757e9=_0x45e30f?function(){const _0x1391c8=_0x4b710a;if(_0xba4ab2){const _0x181863=_0xba4ab2[_0x1391c8(0x37c)](_0x2284a8,arguments);return _0xba4ab2=null,_0x181863;}}:function(){};return _0x45e30f=![],_0x2757e9;}else{if(_0x52d7e6['yDLkj'](_0x1f2c1b[_0x4b710a(0x2d2)],_0x4b710a(0x232)))_0x5c1b49=_0x52d7e6[_0x4b710a(0x1f6)];else{if(_0x52d7e6['yDLkj'](_0x27a7ed[_0x4b710a(0x2d2)],_0x52d7e6['psAps']))_0x386508=_0x52d7e6['EELuM'];else _0x4f1cfc=_0x52d7e6[_0x4b710a(0x3db)];}}};}()),_0x3758e3=_0xd7cd15(this,function(){const _0x4f9bc6=_0x407a,_0x95ea84={'LFaaO':_0x4f9bc6(0x349),'kMxhW':function(_0x1af0b7,_0x1b7b46){return _0x1af0b7===_0x1b7b46;},'olOcE':'VybYK','qxGzQ':function(_0x5613b3,_0x320835){return _0x5613b3+_0x320835;},'wvquh':function(_0x3a69e7,_0x23b160){return _0x3a69e7+_0x23b160;},'ILjrG':_0x4f9bc6(0x1a4),'SYmJm':_0x4f9bc6(0x3a5),'YFESo':function(_0xc8be3f){return _0xc8be3f();},'cShHR':_0x4f9bc6(0x1d9),'OlObO':_0x4f9bc6(0x312),'YMPtL':_0x4f9bc6(0x1a7),'RWUsP':'exception','kBALN':_0x4f9bc6(0x291),'yoqWm':function(_0x2765f1,_0x198d98){return _0x2765f1<_0x198d98;}},_0x478ad4=function(){const _0x469716=_0x4f9bc6;if(_0x95ea84['kMxhW'](_0x95ea84[_0x469716(0x1a1)],_0x95ea84[_0x469716(0x1a1)])){let _0x5b6160;try{_0x5b6160=Function(_0x95ea84[_0x469716(0x364)](_0x95ea84[_0x469716(0x264)](_0x95ea84[_0x469716(0x1c3)],_0x95ea84[_0x469716(0x3ed)]),');'))();}catch(_0x299a59){_0x5b6160=window;}return _0x5b6160;}else{if(_0xa4f9fe[_0x469716(0x288)]()){const _0x3d1c7f=new _0x32ac1d();_0x3d1c7f[_0x469716(0x272)](_0x138ee7),_0x3d1c7f[_0x469716(0x3e4)](_0x524261);}else _0x269b65['canPlayType'](_0x95ea84[_0x469716(0x1eb)])&&(_0x1f755f[_0x469716(0x1e2)]=_0x6c804f);}},_0x3dd594=_0x95ea84['YFESo'](_0x478ad4),_0x5128f8=_0x3dd594[_0x4f9bc6(0x38c)]=_0x3dd594['console']||{},_0x1e7f6d=[_0x95ea84['cShHR'],_0x95ea84['OlObO'],'info',_0x95ea84[_0x4f9bc6(0x1a2)],_0x95ea84['RWUsP'],_0x95ea84[_0x4f9bc6(0x404)],_0x4f9bc6(0x345)];for(let _0x16aaf9=0x0;_0x95ea84[_0x4f9bc6(0x3e2)](_0x16aaf9,_0x1e7f6d[_0x4f9bc6(0x1cd)]);_0x16aaf9++){const _0x1b9253=_0xd7cd15['constructor'][_0x4f9bc6(0x2e6)][_0x4f9bc6(0x1a5)](_0xd7cd15),_0x28d0fd=_0x1e7f6d[_0x16aaf9],_0x1a0acb=_0x5128f8[_0x28d0fd]||_0x1b9253;_0x1b9253[_0x4f9bc6(0x31d)]=_0xd7cd15[_0x4f9bc6(0x1a5)](_0xd7cd15),_0x1b9253['toString']=_0x1a0acb[_0x4f9bc6(0x2dd)][_0x4f9bc6(0x1a5)](_0x1a0acb),_0x5128f8[_0x28d0fd]=_0x1b9253;}});function _0x29a0(){const _0x283f08=['EVziy','TzJHE','DSooS','nav-btn-incorrect','Rituximab','innerHTML','EcBIU','TaJrp','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','2158036MsGYfL','AgpAP','jKsnY','woNkE','explanation_audio_eng','totalTimeResult','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','not-attempted','Obiltoxaximab','SwHpV','yOppm','YHfTX','now','MIfZa','Lung\x20carcinoma','endsWith','accuracyScore','Guttate\x20psoriasis','pcltq','Ptyht','tRqri','resume','quizFile','ClxeZ','ZHbZa','HER2/neu\x20receptor','Aflibercept','not_attempted','timeDisplay','WcLYz','questionIndex','tbuir','770082dIphpT','PzDgE','avgTimeResult','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','<p><strong>Olaratumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20against\x20<strong>PDGFR-alpha</strong>\x20and\x20blocks\x20ligand-mediated\x20receptor\x20activation.&nbsp;It\x20is\x20indicated\x20along\x20<strong>with\x20doxorubicin</strong>\x20for\x20adult\x20patients\x20with\x20<strong>soft\x20tissue\x20sarcoma.</strong>&nbsp;</p>\x0a<p>Panitumumab\x20and\x20cetuximab\x20are\x20monoclonal\x20antibodies\x20against\x20EGFR\x20(HER1).&nbsp;</p>\x0a<p>Pertuzumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20HER2.</p>','correctResult','getItem','ghiKn','lFFRZ','strokeDashoffset','A\x20patient\x20has\x20presented\x20to\x20the\x20OPD\x20with\x20raised\x20erythematous\x20plaques\x20on\x20his\x20arms\x20and\x20torso\x20covered\x20in\x20silvery\x20scales.\x20You\x20decide\x20to\x20prescribe\x20a\x20monoclonal\x20antibody\x20targeting\x20interleukin-23\x20for\x20treatment.\x20Identify\x20this\x20drug.','status','xIhNI','SowGb','YUXPT','FtLov','xODUw','Tildrakizumab','ylTfP','explanation_video','A\x20patient\x20with\x20rheumatoid\x20arthritis\x20has\x20inadequate\x20disease\x20control\x20with\x20methotrexate.\x20Which\x20Janus\x20kinase\x20inhibitor\x20can\x20you\x20add\x20to\x20his\x20treatment\x20regimen?','bGMCp','toString','eVGxK','mjmsW','DTLSI','customQuizData','pVidy','12485APoPpK','fRPIy','OFXAW','prototype','flDOz','DXQNz','iseDD','border-gray-600','correctCount','Mark\x20for\x20Review','hokci','open','Dasatinib','rlEEF','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','lGsWu','yteDG','Baricitinib','Severe\x20rheumatoid\x20arthritis','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','CdwGG','https://dhmbxeygs57ff.cloudfront.net/uploads/ec6b8af55d8d4214adecf78d326084bex1280x1399.JPEG','yKtZV','Conjunctival\x20hemorrhage','timerContainer','qRhzO','TrUsf','question_images','Non-Hodgkin\x20lymphoma','19IVMTjx','markReviewBtn','vHWDn','key','Anti-CD3\x20antibody','Bfipo','filter','CsXVq','oVEPh','fSVxL','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','aMkwq','Which\x20of\x20the\x20following\x20monoclonal\x20antibodies\x20is\x20not\x20a\x20HER1\x20inhibitor?','question_audio','modeModal','vWBRS','Which\x20of\x20the\x20following\x20is\x20a\x20bispecific\x20monoclonal\x20antibody?','LTNNj','warn','selectedAnswer','<p\x20style=\x22text-align:\x20left;\x22>The\x20scenario\x20described\x20in\x20the\x20question\x20points\x20towards\x20a\x20diagnosis\x20of<strong>\x20chronic\x20plaque\x20psoriasis.\x20Tildrakizumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20directed\x20<strong>against&nbsp;IL-23\x20</strong>used\x20in\x20the\x20treatment\x20of\x20this\x20condition<strong>.</strong></p>\x0a<p\x20style=\x22text-align:\x20left;\x22>IL-23\x20is&nbsp;a\x20naturally\x20occurring\x20cytokine\x20that\x20is\x20involved\x20in\x20inflammatory\x20and\x20immune\x20responses.\x20Tildrakizumab\x20prevents\x20the\x20interaction\x20of\x20IL-23\x20with\x20its\x20receptors.\x20It&nbsp;is\x20indicated\x20in\x20moderate-to-severe\x20plaque\x20psoriasis.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22><strong>Secukinumab,\x20ixekizumab,\x20brodalumab</strong>\x20are\x20other\x20monoclonal\x20antibodies\x20directed\x20against\x20<strong>IL-17A</strong>\x20and\x20indicated\x20in\x20moderate-to-severe\x20plaque\x20psoriasis.</p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Note:\x20<strong>Ustekinumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20against\x20<strong>both\x20IL-12\x20and\x20IL-23</strong>.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20Crohn\x27s\x20disease,\x20ulcerative\x20colitis,\x20plaque\x20psoriasis\x20and\x20psoriatic\x20arthritis.</p>','Anal\x20canal\x20carcinoma','hPBkz','div','JgSoc','ecwkN','aLGbb','dataset','currentMode','__proto__','A\x20patient\x20diagnosed\x20with\x20wet\x20age-related\x20macular\x20degeneration\x20is\x20being\x20administered\x20ranibizumab\x20intravitreally.\x20All\x20of\x20the\x20following\x20are\x20known\x20side\x20effects\x20of\x20the\x20drug,\x20except\x20_______.','ixCgO','remove','explanation_audio_hin','wiFSF','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','Olaratumab','Correct','7210EjehUp','nav-btn-current','stats','reduce','jXMkG','BNQDD','gggGr','MZMYu','saaKs','questionNav','EfQKN','HlfDt','push','QOEBn','VioEw','rbZlC','NXNnB','AwqYm','bLkyU','SegmI','Urothelial\x20cancer','qGKPi','Palliation\x20in\x20head\x20and\x20neck\x20cancer','zeXOW','gBTOh','paEAO','tXXsE','totalAttempted','14FuXUBP','green','vSAgC','trace','It\x20is\x20an\x20antibody\x20produced\x20entirely\x20from\x20mouse\x20containing\x20no\x20human\x20component','notAttemptedResult','stBso','application/vnd.apple.mpegurl','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','Abciximab','Ofoua','hidden','Not\x20Attempted','setItem','display','lsXzr','Trastuzumab','border-green-500','solutionText','Ixekizumab','strokeDasharray','WaoTE','bNEdV','XVjno','submitSection','classList','text','data-option-index','isArray','href','oNrFe','rnUrV','solutionContainer','ArrowRight','qxGzQ','YXDnM','Merwi','YZOYh','accuracy','addEventListener','markReviewText','ZfWiP','nBlmT','JEVkc','totalQuestions','\x22\x20data-option-index=\x22','<p><strong>Ibritumomab\x20tiuxetan</strong>\x20is\x20a\x20<strong>radioimmunoconjugate</strong>\x20that&nbsp;is\x20approved\x20for\x20use\x20in\x20non-Hodgkin\x27s\x20lymphoma.\x20<strong>Diffuse\x20large\x20B-cell\x20lymphoma</strong>&nbsp;is\x20a\x20subtype\x20of\x20<strong>non-Hodgkin\x27s\x20lymphoma.</strong></p>\x0a<p>Ibritumomab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD20\x20which\x20is\x20attached\x20to\x20the\x20radioactive\x20isotope\x20yttrium-90\x20using\x20the\x20chelator\x20tiuxetan.\x20Beta\x20emission\x20from\x20Y-90\x20destroys\x20the\x20surrounding\x20tissues.&nbsp;</p>\x0a<p>Radioimmunoconjugates\x20provide\x20targeted\x20delivery\x20of\x20radionuclides\x20to\x20tumor\x20cells.\x20It&nbsp;is\x20made\x20by\x20attaching\x20a\x20radioactive\x20molecule\x20to\x20a\x20monoclonal\x20antibody.&nbsp;</p>\x0a<p>Option\x20A:\x20Gemtuzumab\x20ozogamicin\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD33\x20covalently\x20linked\x20to\x20a\x20semisynthetic\x20derivative\x20of\x20calicheamicin\x20which\x20is\x20a\x20potent\x20antitumor\x20antibiotic.&nbsp;</p>\x0a<p>Option\x20B:\x20Brentuximab\x20vedotin\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD30\x20linked\x20with\x20microtubule\x20disrupting\x20agent\x20MMAE.&nbsp;</p>\x0a<p>Option\x20C:\x20Denileukin\x20diftitox\x20is\x20an\x20immunotoxin\x20produced\x20by\x20genetic\x20recombination\x20of\x20IL-2\x20and\x20the\x20catalytically\x20active\x20fragment\x20of\x20diphtheria\x20toxin.</p>','Gemtuzumab\x20ozogamicin','xnXGA','yKjnX','DdieN','cnmpT','EClRz','uWApG','questions','EdTnJ','wMqzH','\x20-\x20Brain\x20And\x20Scalpel','apply','LIiEg','GEshe','DxzVe','UfBcJ','bXyfi','pathname','quizPerformanceData','xVCkl','correctAnswers','Pharmacology','Secukinumab','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','WvugF','bxtZu','2337848izxxqr','console','gMsVo','startAt','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','RszzW','A\x2070-year-old\x20man\x20is\x20found\x20to\x20have\x20leukocytosis\x20on\x20his\x20yearly\x20health\x20check-up.\x20\x20Further\x20evaluation\x20led\x20to\x20a\x20diagnosis\x20of\x20chronic\x20lymphocytic\x20leukemia.\x20Immunophenotyping\x20was\x20positive\x20for\x20CD52.\x20Which\x20is\x20the\x20monoclonal\x20antibody\x20indicated\x20in\x20this\x20condition?','QAYjv','hnmaV','nkuvS','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','pebPK','hqslC','getElementById','floor','Cetuximab\x20is\x20approved\x20for\x20use\x20in\x20which\x20of\x20the\x20following\x20conditions?','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','tmVbl','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','IYZpg','ZvYNs','createElement','qKKhJ','Panitumumab','HxiNY','lDewd','{}.constructor(\x22return\x20this\x22)(\x20)','EGFR','none','nav-btn-correct','border-red-500','Paroxysmal\x20nocturnal\x20hemoglobinuria','SCRsT','Previous\x20progress\x20cleared.','hvUuC','WOlxz','Which\x20of\x20the\x20following\x20is\x20the\x20monoclonal\x20antibody\x20developed\x20against\x20Bacillus\x20anthracis?','No\x20solution\x20available.','xrQQq','JQRRh','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','incomplete','HrevR','ENeKd','Which\x20of\x20the\x20following\x20is\x20an\x20immune\x20checkpoint\x20inhibitor?','DGBDd','Marked','quizHierarchy','location','EuqBq','Which\x20of\x20the\x20following\x20drugs\x20is\x20recently\x20approved\x20for\x20the\x20treatment\x20of\x20colorectal\x20cancer\x20arising\x20through\x20Lynch\x20Syndrome?','xYRXs','byQCi','Metastatic\x20squamous\x20cell\x20lung\x20cancer','style','incorrectAnswers','study','FxZJK','jttmf','add','solutionAudio','ybScy','AnGSt','<div\x20class=\x22mt-4\x22><img\x20src=\x22','bKZhs','Jpbep','Durvalumab','A\x202-year-old\x20girl\x20was\x20brought\x20to\x20the\x20hospital\x20by\x20her\x20mother\x20with\x20complaints\x20of\x20abdominal\x20pain\x20and\x20diarrhea.\x20Examination\x20revealed\x20a\x20palpable\x20abdominal\x20mass.\x20Investigations\x20showed\x20elevated\x20levels\x20of\x20urinary\x20homovanillic\x20acid\x20and\x20vanillyl\x20mandelic\x20acid.\x20The\x20lesion\x20could\x20not\x20be\x20completely\x20resected\x20during\x20surgery\x20and\x20histopathology\x20findings\x20are\x20shown\x20in\x20the\x20image.\x20Which\x20of\x20the\x20following\x20is\x20a\x20monoclonal\x20antibody\x20approved\x20for\x20use\x20in\x20this\x20condition?','includes','jIngH','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','ItzRh','lECnU','qecAD','querySelectorAll','XFAuy','bookmarkedQuestions','Bookmarked','xXLsu','1361055NrIJZs','VRdTc','OcCKg','get','https://dhmbxeygs57ff.cloudfront.net/uploads/865333df5e6d4bc6944f21720fcf027cx1280x1096.JPEG','HKqhj','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','Blinatumomab','yoqWm','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','attachMedia','map','nrOQJ','className','rOLjO','WWqou','ArlMM','qjkWn','PpAaA','SYmJm','ecLwu','questionStates','.option-button','reload','currentQuestion','IhDuv','Hscwg','solutionImages','iIBpa','0|4|2|1|5|3','test','search','raTKL','Ranibizumab','mkRYR','IYuIn','xJANK','RTRBq','cBgmo','fromCharCode','9AZCJHV','Kuhaf','kBALN','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','OMjKg','FrHsh','timed_exam','It\x20is\x20a\x20monoclonal\x20antibody\x20produced\x20by\x20injecting\x20HER-2\x20antigen','JDjYy','tPqsu','ykBRX','XDLoV','npWwr','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','fGcdZ','ETsXZ','optionsContainer','Cardiotoxicity','xIjAc','YHbyP','currentQuestionIndex','Clnyi','prevBtn','pLYAb','appendChild','AmqQN','scoreCircle','QNAUt','custom_quiz.html','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','performanceModal','AjDGA','timeSpent','</span><span>','No\x20solution\x20provided','KFsgb','wVAAc','xFBGu','tbBhe','quizSidebar','hierarchy','66-monoclonal-antibodies-d586b3df.html','nav-btn-marked-review','jiFps','yxAop','pyPhF','OSWiW','vmQAU','5RWvTOj','olOcE','YMPtL','bookmarked','return\x20(function()\x20','bind','Neurotoxicity','error','questionMedia','PHoVf','HgaJw','sWPcf','RnOdX','Ototoxicity','iGCVG','FYKVz','szrrg','fdGNX','Refractory\x20classical\x20hodgkin’s\x20lymphoma','reviewQuestionsContainer','SeVmI','Denileukin\x20deftitox','khYpK','qBank','23636388RUjKnJ','66\x20Monoclonal\x20Antibodies','gray','totalTime','2|5|1|3|0|4','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','incorrectCount','uSdJh','epqEx','Iaqbj','selected','ILjrG','wFdOn','answered','<p>The\x20most\x20serious\x20<strong>toxicity</strong>\x20of\x20<strong>trastuzumab</strong>\x20is\x20<strong>cardiac\x20failure</strong>.\x20Cardiac\x20failure\x20is\x20a\x20<strong>potentially\x20disabling</strong>\x20or\x20<strong>fatal</strong>\x20side\x20effect\x20unless\x20recognized\x20early\x20and\x20the\x20drug\x20is\x20discontinued.</p>\x0a<p>Cardiotoxicity\x20is\x20caused\x20by\x20the\x20interruption\x20of\x20HER2/4\x20heterodimer\x20signaling\x20in\x20cardiomyocytes,\x20which\x20is\x20a\x20type\x20of\x20signaling\x20that\x20is\x20essential\x20for\x20the\x20maintenance\x20of\x20contractile\x20function.</p>\x0a<p>Clinical\x20correlation:</p>\x0a<ul>\x0a<li>Baseline\x20<strong>ECG</strong>\x20and\x20cardiac<strong>\x20ejection\x20fraction</strong>\x20should\x20be\x20<strong>monitored</strong>\x20to\x20rule\x20out\x20underlying\x20heart\x20disease</li>\x0a<li>Careful\x20<strong>clinical\x20follow-up</strong>\x20for\x20signs\x20and\x20symptoms\x20of\x20CHF</li>\x0a</ul>\x0a<p>Other\x20side\x20effects\x20include&nbsp;fever,\x20chills,\x20nausea,\x20dyspnea,\x20and\x20rashes.</p>\x0a<p>Dose-limiting\x20toxicities\x20are\x20side\x20effects\x20of\x20a\x20drug\x20or\x20other\x20treatment\x20that\x20are\x20serious\x20enough\x20to\x20prevent\x20an\x20increase\x20in\x20dose\x20or\x20level\x20of\x20that\x20treatment.</p>','sZGfZ','jScIp','PJHwK','JDBmh','xlKjY','<div><strong>Basiliximab</strong>&nbsp;exhibits\x20a\x20high\x20affinity\x20towards<strong>\x20IL-2\x20receptor</strong>\x20and\x20<strong>inhibits</strong>\x20it.\x20It\x20is\x20an\x20anti-\x20CD-25\x20monoclonal\x20antibody.</div>\x0a<div>It\x20has\x20a\x20short\x20plasma\x20half-life\x20of\x201\x20week.\x20It\x20is\x20used\x20to\x20prevent\x20transplant\x20rejection\x20reactions.\x20Its\x20adverse\x20effects\x20are\x20anaphylactic\x20reactions\x20&amp;\x20opportunistic\x20infections.</div>','length','Bookmark','Fall\x20in\x20IOP','Pertuzumab','MpnPB','padStart','referrer','What\x20is\x20basiliximab?','Reslizumab','Nivolumab','Which\x20among\x20the\x20following\x20is\x20the\x20Interleukin-5\x20antagonist\x20indicated\x20in\x20the\x20management\x20of\x20asthma?','MfyGK','log','choices','round','forEach','DzPSx','MwcNI','Obinutuzumab','LEYIw','bRHBH','src','fIVPD','JEqhs','jxAhR','split','imtxS','gKJMq','canPlayType','\x22\x20data-src=\x22','LFaaO','trGHq','userHistory','ssheg','Omalizumab','ApgmE','pfsWI','WJOKq','Brodalumab','aKjFz','pop','xbTxJ','IFJHe','button','iBpNx','VPIXk','iaAFf','A\x2057-year-old\x20woman\x20is\x20diagnosed\x20with\x20HER\x202/neu\x20positive\x20breast\x20cancer.\x20Which\x20of\x20the\x20following\x20monoclonal\x20antibodies\x20is\x20indicated\x20for\x20the\x20management\x20of\x20this\x20patient?','sUVoY','</span></div>','sPadP','VApnN','sNquu','89150tMxBjS','questionReviewSection','zWgJL','Bevacizumab','keydown','wcWPZ','asZFF','incorrect','WpgEd','FIkpB','<p><strong>Pembrolizumab</strong>\x20is\x20<strong>not</strong>\x20approved\x20for\x20use\x20in\x20<strong>non-metastatic</strong>\x20small-cell\x20lung\x20cancer.\x20It\x20is\x20<strong>approved</strong>\x20for\x20<strong>metastatic</strong>\x20small\x20cell\x20lung\x20cancer\x20(SCLC).</p>\x0a<p>Pembrolizumab\x20is\x20a\x20monoclonal\x20antibody\x20(IgG4)\x20against\x20PD-1\x20and\x20blocks\x20interaction\x20between\x20PD-1\x20and\x20its\x20ligands\x20PD-L1\x20and\x20PD-L2.\x20It\x20is\x20used\x20in\x20the\x20following\x20conditions:</p>\x0a<ul>\x0a<li><strong>Metastatic\x20SCLC\u00a0</strong></li>\x0a<li><strong>Hodgkin’s\x20lymphoma</strong></li>\x0a<li>Metastatic\x20<strong>urothelial\x20cancer</strong></li>\x0a<li><strong>Metastatic\u00a0non\x20SCLC</strong></li>\x0a<li>Merkel\x20cell\x20carcinoma</li>\x0a<li>Chemotherapy-refractory\x20head\x20and\x20neck\x20cancers</li>\x0a<li>Refractory\x20melanoma</li>\x0a<li>Triple-Negative\x20Breast\x20Cancer</li>\x0a<li>Esophageal\x20Cancer</li>\x0a<li>Colorectal\x20cancer\x20due\x20to\x20Lynch\x20syndrome</li>\x0a</ul>','Hiekh','tUzuQ','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','LpnzT','question_video','Progress\x20loaded.','ZWqpN','It\x20is\x20a\x20polyclonal\x20antibody','block','constructor','flex','jXrAl','nqZkD','zMdyd','Veqyc','idivc','QvHJD','toLowerCase','Cetuximab','DRoKR','Rituximab\x20is\x20not\x20used\x20in\x20which\x20of\x20the\x20following\x20conditions?','rhyNK','dkgFn','textContent','aPaDS','IDDXF','name','UZoCq','Ramucirumab','Ibritumomab\x20tiuxetan','IenWI','BmPIM','WwTeC','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','bookmarkBtn','gOCtM','<p><strong>Cetuximab</strong>\x20is\x20used\x20for\x20<strong>palliation</strong>\x20in\x20<strong>head</strong>\x20and\x20<strong>neck\x20cancer.</strong></p>\x0a<p><strong>Indications</strong>\x20for\x20use\x20of\x20cetuximab\x20are:</p>\x0a<ul>\x0a<li><strong>Advanced\x20squamous\x20cell\x20carcinoma</strong>\x20of\x20the\x20<strong>head</strong>\x20and<strong>\x20neck</strong>\x20in&nbsp;combination\x20with\x20radiotherapy\x20for\x20locally\x20or\x20regionally&nbsp;</li>\x0a<li><strong>Metastatic\x20colorectal</strong>\x20cancer</li>\x0a</ul>\x0a<p>Cetuximab\x20is\x20a\x20recombinant\x20chimeric\x20monoclonal\x20antibody\x20against\x20the\x20external\x20domain\x20of\x20the\x20epidermal\x20growth\x20factor\x20receptor\x20(EGFR).</p>','correct','QvFdM','KLiNr','GGMBJ','Alemtuzumab','ujiAB','Xbpaz','RdpVa','WcRZv','UJZlj','LDdOB','foAej','VEGF\x20receptor','fill','SOZwY','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','<p><strong>Alemtuzumab</strong>\x20is\x20a\x20humanized\x20<strong>monoclonal\x20antibody\x20against\x20CD52</strong>\x20that\x20is\x20indicated\x20in\x20the\x20management\x20of\x20<strong>chronic\x20lymphocytic\x20leukemia</strong>\x20(CLL).</p>\x0a<p>Rituximab\x20and\x20obinutuzumab\x20are\x20monoclonal\x20antibodies\x20against\x20CD20\x20that\x20are\x20also\x20indicated\x20in\x20the\x20treatment\x20of\x20chronic\x20lymphocytic\x20leukemia.</p>\x0a<p>Cetuximab\x20is\x20a\x20chimeric&nbsp;human-mouse\x20anti-epidermal\x20growth\x20factor\x20receptor\x20monoclonal\x20antibody\x20against\x20the\x20extracellular\x20domain\x20of\x20EGFR.</p>','chPFp','contains','xoSeQ','kRSUO','JYVrt','findIndex','kQehg','OCYAo','questionText','index.html','Lebrikizumab','review-question\x20','GvesJ','testModeReviewLegend','timed_study','ZlMgy','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','<p><strong>Pertuzumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20against\x20the&nbsp;<strong>HER2\x20receptor.</strong>&nbsp;</p>\x0a<p>Pertuzumab\x20is\x20indicated\x20in\x20HER2-positive<strong>&nbsp;breast\x20cancer</strong>\x20in\x20combination\x20with\x20trastuzumab\x20and\x20docetaxel.&nbsp;</p>\x0a<p>Monoclonal\x20<strong>antibodies\x20against\x20EGFR</strong>\x20(<strong>HER1</strong>)\x20are:</p>\x0a<ul>\x0a<li>Panitumumab</li>\x0a<li>Cetuximab</li>\x0a<li>Necitumumab</li>\x0a</ul>','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','explanation_images','-600\x20text-white\x22>','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','click','<p><strong>Rituximab</strong>\x20is\x20used\x20in\x20all\x20conditions,\x20except\x20paroxysmal\x20nocturnal\x20hemoglobinuria.</p>\x0a<p><strong>Indications</strong>\x20for\x20<strong>rituximab</strong>\x20include:\x20(mnemonic-\x20CANT\x20MIS\x20Ritu):</p>\x0a<ul>\x0a<li><strong>C</strong>LL</li>\x0a<li><strong>A</strong>utoimmune\x20hemolytic\x20anemia</li>\x0a<li><strong>N</strong>on-Hodgkin\x20lymphoma</li>\x0a<li><strong>T</strong>TP</li>\x0a<li><strong>M</strong>arginal\x20zone\x20lymphomas,\x20mantle\x20cell\x20lymphoma,\x20myasthenia\x20gravis</li>\x0a<li><strong>I</strong>TP</li>\x0a<li><strong>S</strong>LE</li>\x0a<li><strong>R</strong>heumatoid\x20arthritis</li>\x0a</ul>\x0a<p>It\x20is\x20a\x20<strong>chimeric\x20monoclonal\x20antibody</strong>\x20targeted\x20against\x20the<strong>\x20CD20\x20receptor</strong>&nbsp;that\x20is\x20present\x20on\x20the<strong>\x20surface\x20of\x20B\x20lymphocytes.</strong></p>\x0a<p>Ofatumumab\x20and\x20obinutuzumab\x20are\x20the\x20other\x20monoclonal\x20antibodies\x20directed\x20against\x20CD20\x20receptors.&nbsp;They\x20are\x20also\x20approved\x20for\x20use\x20in\x20CLL.</p>','SbrGe','qlRsF','tFMMx','A\x20patient\x20was\x20diagnosed\x20with\x20HER2/neu\x20positive\x20breast\x20cancer\x20and\x20was\x20started\x20on\x20adjuvant\x20therapy\x20with\x20trastuzumab.\x20Which\x20of\x20the\x20following\x20is\x20the\x20most\x20serious\x20and\x20dose-limiting\x20toxicity\x20of\x20this\x20drug?','video[data-src]','WppFz','HIdhj','<p><strong>Panitumumab</strong>\x20is\x20a\x20recombinant\x20fully-humanized\x20<strong>monoclonal\x20antibody</strong>\x20that\x20binds\x20specifically\x20to\x20the\x20external\x20domain\x20of\x20the\x20epidermal\x20growth\x20factor\x20receptor\x20(<strong>EGFR</strong>).<strong>&nbsp;</strong></p>\x0a<p>It\x20is\x20approved\x20for\x20use\x20in\x20patients\x20with\x20<strong>metastatic\x20colorectal\x20carcinoma</strong>.</p>','wvquh','Icyvz','YXTTq','parse','solution','QbRHO','bbSTw','OauCc','<p\x20style=\x22text-align:\x20justify;\x22><strong>Durvalumab&nbsp;</strong>is\x20an\x20immune\x20checkpoint\x20inhibitor.\x20It\x20is\x20an\x20<strong>antagonist\x20of\x20PD-L1</strong>\x20which\x20is\x20a\x20protein-ligand\x20that\x20is\x20present\x20on\x20antigen-presenting\x20cells,\x20T\x20cells,\x20B\x20cells,\x20and\x20some\x20cancer\x20cells.</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22><strong>Immune\x20checkpoint\x20inhibitors</strong>\x20inhibit\x20proteins\x20that\x20help\x20the\x20cancer\x20cells\x20evade\x20the\x20immune\x20response.\x20When\x20these\x20proteins\x20are\x20blocked,\x20the\x20brake\x20on\x20the\x20immune\x20system\x20is\x20released\x20and\x20T\x20cells\x20are\x20able\x20to\x20kill\x20cancer\x20cells\x20more\x20efficiently.</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Durvalumab\x20is\x20approved\x20for\x20use\x20in&nbsp;<strong>metastatic\x20urothelial</strong>\x20and\x20<strong>Merkel\x20cell\x20cancer</strong>.&nbsp;The\x20FDA\x20approved\x20Durvalumab\x20in\x20combination\x20with\x20etoposide\x20and\x20either\x20carboplatin\x20or\x20cisplatin\x20as\x20first-line\x20treatment\x20of\x20patients\x20with\x20<strong>extensive-stage\x20small-cell\x20lung\x20cancer</strong>.</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Other\x20PD-L1\x20inhibitors\x20include:</p>\x0a<ul>\x0a<li\x20style=\x22text-align:\x20justify;\x22>Atezolizumab</li>\x0a<li\x20style=\x22text-align:\x20justify;\x22>Avelumab</li>\x0a<li\x20style=\x22text-align:\x20justify;\x22>Durvalumab</li>\x0a</ul>','Dupilumab\x20is\x20indicated\x20in\x20the\x20management\x20of\x20_______.','Which\x20of\x20the\x20following\x20is\x20a\x20monoclonal\x20antibody\x20directed\x20against\x20PDGFR-alpha?','cVFKr','lkniD','Denosumab','loadSource','TpmfU','solutionVideo','zfLDD','GtOOP','Alirocumab','Ponatinib','notAttempted','Resistant\x20osteoporosis','.m3u8','JWhFt','WOmoZ','markedForReview','A\x20patient\x20diagnosed\x20with\x20metastatic\x20colorectal\x20carcinoma\x20is\x20being\x20treated\x20with\x20panitumumab.\x20This\x20drug\x20acts\x20against\x20which\x20of\x20the\x20following\x20receptors?','replace','ngOyj','zqzrj','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','nvCJP','true','RHlXO','pcWcT','isSupported','toISOString','JXVKQ','lvQxv','umDYi','correct_choice_id','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','navBtn_','mfNNQ','table','bookmarkText','TdhYH','SoMvH','ySPbo','yDLkj','stringify','incorrectResult','HglZN','NeSAe','hdIxn','cqspy'];_0x29a0=function(){return _0x283f08;};return _0x29a0();}_0x3758e3();let questionsData=[{'text':_0x2370d7(0x39a),'choices':[{'id':0x1,'text':_0x2370d7(0x33c)},{'id':0x2,'text':_0x2370d7(0x315)},{'id':0x3,'text':'Gastric\x20carcinoma'},{'id':0x4,'text':_0x2370d7(0x2b5)}],'correct_choice_id':0x1,'solution':_0x2370d7(0x231),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x27f),'choices':[{'id':0x1,'text':'PDGFR'},{'id':0x2,'text':_0x2370d7(0x3a6)},{'id':0x3,'text':_0x2370d7(0x2c0)},{'id':0x4,'text':_0x2370d7(0x23e)}],'correct_choice_id':0x2,'solution':_0x2370d7(0x263),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x1fc),'choices':[{'id':0x1,'text':'Panitumumab'},{'id':0x2,'text':_0x2370d7(0x21f)},{'id':0x3,'text':_0x2370d7(0x352)},{'id':0x4,'text':_0x2370d7(0x205)}],'correct_choice_id':0x3,'solution':'<p><strong>Trastuzumab</strong>\x20is\x20indicated\x20for\x20<strong>adjuvant</strong>\x20therapy\x20in\x20early\x20and\x20metastatic\x20<strong>HER2\x20positive\x20breast\x20cancer</strong>.&nbsp;</p>\x0a<p>Trastuzumab\x20is\x20a\x20humanized\x20monoclonal\x20antibody\x20that\x20binds\x20to\x20the\x20extracellular\x20domain\x20of\x20HER2/Neu.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201213\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Human\x20epidermal\x20growth\x20factor\x20receptor\x202\x20tyrosine\x20kinase\x20receptor\x20(<strong>HER-2-TK</strong>)\x20<strong>inhibitors</strong>\x20are:</p>\x0a<ul>\x0a<li>Lapatinib</li>\x0a<li>Neratinib</li>\x0a</ul>\x0a<p><strong>Anti-Her-2\x20monoclonal\x20antibodies</strong>\x20are:</p>\x0a<ul>\x0a<li>Trastuzumab</li>\x0a<li>Pertuzumab</li>\x0a</ul>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2057-year-old\x20woman\x20diagnosed\x20with\x20breast\x20carcinoma\x20was\x20prescribed\x20trastuzumab.\x20Which\x20of\x20the\x20following\x20statements\x20regarding\x20this\x20drug\x20is\x20true?','choices':[{'id':0x1,'text':_0x2370d7(0x346)},{'id':0x2,'text':_0x2370d7(0x409)},{'id':0x3,'text':_0x2370d7(0x214)},{'id':0x4,'text':'It\x20is\x20a\x20monoclonal\x20antibody\x20containing\x20only\x20human\x20component'}],'correct_choice_id':0x2,'solution':'<p><strong>Trastuzumab</strong>\x20is\x20a\x20<strong>humanized\x20monoclonal\x20antibody</strong>\x20against\x20the\x20external\x20domain\x20of\x20<strong>HER2/neu.</strong>\x20In\x20humanized\x20antibodies,\x20all\x20components\x20are\x20identical\x20to\x20human\x20antibodies\x20(95%\x20human\x20component),\x20except\x20the\x20complementary\x20region\x20of\x20the\x20variable\x20chain\x20that\x20<strong>contains\x20sequences</strong>\x20from<strong>\x20other\x20species</strong>.</p>\x0a<p>It&nbsp;is\x20indicated\x20in\x20the\x20management\x20of\x20<strong>adjuvant\x20therapy</strong>\x20in\x20<strong>early</strong>\x20and\x20<strong>metastatic\x20HER-2\x20positive\x20breast\x20cancer.</strong>&nbsp;</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201213\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Human\x20epidermal\x20growth\x20factor\x20receptor\x202\x20tyrosine\x20kinase\x20receptor\x20(<strong>HER-2-TK</strong>)\x20<strong>inhibitors</strong>\x20are:</p>\x0a<ul>\x0a<li>Lapatinib</li>\x0a<li>Neratinib</li>\x0a</ul>\x0a<p><strong>Anti-Her-2\x20monoclonal\x20antibodies</strong>\x20are:</p>\x0a<ul>\x0a<li>Trastuzumab</li>\x0a<li>Pertuzumab</li>\x0a</ul>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x25f),'choices':[{'id':0x1,'text':'Nephrotoxicity'},{'id':0x2,'text':_0x2370d7(0x1a6)},{'id':0x3,'text':_0x2370d7(0x413)},{'id':0x4,'text':_0x2370d7(0x1ad)}],'correct_choice_id':0x3,'solution':_0x2370d7(0x1c6),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x31e),'choices':[{'id':0x1,'text':'Eye\x20pain'},{'id':0x2,'text':_0x2370d7(0x1cf)},{'id':0x3,'text':_0x2370d7(0x2fa)},{'id':0x4,'text':'Floaters'}],'correct_choice_id':0x2,'solution':'<p><strong>Ranibizumab&nbsp;</strong>is\x20associated\x20with\x20a\x20raise\x20in\x20IOP,\x20not\x20a\x20fall.</p>\x0a<p><strong>Ranibizumab</strong>\x20is\x20a&nbsp;monoclonal\x20antibody\x20directed\x20against\x20VEGF-A\x20(vascular\x20endothelial\x20growth\x20factor-A).&nbsp;Ranibizumab\x20is\x20indicated\x20in<strong>\x20wet\x20age-related\x20macular\x20degeneration\x20</strong>and\x20is\x20used<strong>\x20intravitreally\x20</strong>where\x20it<strong>\x20inhibits\x20VEGF-A\x20induced\x20ocular\x20neovascularization.</strong></p>','explanation_video':'','question_images':[],'explanation_images':[_0x2370d7(0x2f8)]},{'text':'Which\x20among\x20the\x20following\x20is\x20the\x20monoclonal\x20antibody\x20that\x20is\x20targeted\x20specifically\x20against\x20VEGFR?','choices':[{'id':0x1,'text':_0x2370d7(0x205)},{'id':0x2,'text':_0x2370d7(0x3fb)},{'id':0x3,'text':_0x2370d7(0x229)},{'id':0x4,'text':_0x2370d7(0x2c1)}],'correct_choice_id':0x3,'solution':'<p><strong>Ramucirumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20binds\x20to\x20<strong>VEGFR-2</strong>\x20and\x20inhibits\x20the\x20binding\x20of\x20VEGFR\x20ligands.&nbsp;It\x20is\x20indicated\x20in\x20<strong>NSCLC,\x20gastric</strong>\x20cancer\x20and\x20<strong>metastatic\x20colorectal</strong>\x20cancer.&nbsp;</p>\x0a<p>Bevacizumab,\x20aflibercept\x20and\x20ranibizumab\x20are\x20monoclonal\x20antibodies\x20against\x20VEGF\x20ligands\x20and\x20not\x20the\x20receptor.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x221),'choices':[{'id':0x1,'text':_0x2370d7(0x2ff)},{'id':0x2,'text':_0x2370d7(0x3aa)},{'id':0x3,'text':'Rheumatoid\x20arthritis'},{'id':0x4,'text':'Systemic\x20lupus\x20ertythematosis'}],'correct_choice_id':0x2,'solution':_0x2370d7(0x25b),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x391),'choices':[{'id':0x1,'text':_0x2370d7(0x2a1)},{'id':0x2,'text':'Alemtuzumab'},{'id':0x3,'text':_0x2370d7(0x21f)},{'id':0x4,'text':_0x2370d7(0x1df)}],'correct_choice_id':0x2,'solution':_0x2370d7(0x242),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x30c),'choices':[{'id':0x1,'text':_0x2370d7(0x1d0)},{'id':0x2,'text':'Cetuximab'},{'id':0x3,'text':'Necitumumab'},{'id':0x4,'text':_0x2370d7(0x3a2)}],'correct_choice_id':0x1,'solution':_0x2370d7(0x254),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x26e),'choices':[{'id':0x1,'text':'Panitumumab'},{'id':0x2,'text':'Pertuzumab'},{'id':0x3,'text':'Cetuximab'},{'id':0x4,'text':_0x2370d7(0x324)}],'correct_choice_id':0x4,'solution':_0x2370d7(0x2cb),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x310),'choices':[{'id':0x1,'text':'Daratumumab'},{'id':0x2,'text':'Alemtuzumab'},{'id':0x3,'text':_0x2370d7(0x3e1)},{'id':0x4,'text':_0x2370d7(0x3a2)}],'correct_choice_id':0x3,'solution':'<p><strong>Blinatumomab</strong>\x20is\x20a\x20<strong>bispecific\x20monoclonal\x20antibody.</strong>&nbsp;</p>\x0a<p>Bispecific\x20monoclonal\x20antibody\x20<strong>simultaneously</strong>\x20binds\x20to\x20<strong>two\x20different\x20types</strong>\x20of&nbsp;<strong>antigen.</strong>\x20It&nbsp;binds\x20simultaneously\x20to\x20<strong>CD3\x20on\x20T\x20cells</strong>\x20and\x20to\x20<strong>CD19\x20on\x20B\x20cells</strong>.\x20This\x20links\x20the\x20two\x20cells\x20and\x20activates\x20T\x20cells\x20to\x20exert\x20cytotoxic\x20activity\x20against\x20CD19\x20B\x20cells.&nbsp;</p>\x0a<p>Blinatumomab&nbsp;is\x20approved\x20for\x20the\x20treatment\x20of\x20Philadelphia\x20chromosome-negative&nbsp;relapsed\x20or\x20refractory\x20B-cell\x20precursor\x20ALL<strong>.&nbsp;</strong></p>\x0a<p>Option\x20A:\x20Daratumumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD-38.&nbsp;</p>\x0a<p>Option\x20B:\x20Alemtuzumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20CD-52.&nbsp;</p>\x0a<p>Option\x20D:\x20Panitumumab\x20is\x20a\x20monoclonal\x20antibody\x20against\x20EGFR.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2040-year-old\x20man\x20who\x20presented\x20with\x20fever,\x20night\x20sweats\x20and\x20weight\x20loss\x20was\x20evaluated\x20and\x20diagnosed\x20with\x20diffuse\x20large\x20B-cell\x20lymphoma.\x20Which\x20of\x20the\x20following\x20is\x20a\x20radioimmunoconjugate\x20that\x20can\x20be\x20used\x20in\x20this\x20condition?','choices':[{'id':0x1,'text':_0x2370d7(0x371)},{'id':0x2,'text':'Brentuximab\x20vedotin'},{'id':0x3,'text':_0x2370d7(0x1b5)},{'id':0x4,'text':_0x2370d7(0x22a)}],'correct_choice_id':0x4,'solution':_0x2370d7(0x370),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x1d4),'choices':[{'id':0x1,'text':'IL-1\x20receptor\x20antagonist'},{'id':0x2,'text':_0x2370d7(0x304)},{'id':0x3,'text':'IL-2\x20receptor\x20antagonist'},{'id':0x4,'text':'TNF\x20inhibitor'}],'correct_choice_id':0x3,'solution':_0x2370d7(0x1cc),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x3ce),'choices':[{'id':0x1,'text':_0x2370d7(0x277)},{'id':0x2,'text':_0x2370d7(0x236)},{'id':0x3,'text':'Dinutuximab'},{'id':0x4,'text':_0x2370d7(0x271)}],'correct_choice_id':0x3,'solution':'<p>The\x20given\x20scenario\x20and\x20the\x20histopathology\x20(image)\x20showing\x20small\x20round\x20blue\x20tumor\x20cells\x20with\x20<strong>Homer-Wright\x20pseudorosettes</strong>,\x20point\x20towards\x20a\x20diagnosis\x20of\x20paediatric<strong>\x20neuroblastoma.\x20D</strong><strong>inutuximab</strong>\x20is\x20the\x20<strong>monoclonal\x20antibody</strong>\x20against\x20glycolipid\x20<strong>GD2</strong>\x20which\x20is\x20indicated\x20in\x20this\x20condition.</p>\x0a<p>GD2\x20glycolipid\x20is\x20expressed\x20on\x20neuroblastoma\x20cells\x20and\x20on\x20normal\x20cells\x20of\x20neuroectodermal\x20origin,\x20including\x20the\x20central\x20nervous\x20system\x20and\x20peripheral\x20nerves.</p>','explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/da6232ea8f694e2382067f8c07e0ef17.JPEG'],'explanation_images':[_0x2370d7(0x3de)]},{'text':_0x2370d7(0x3bd),'choices':[{'id':0x1,'text':'Ipilimumab'},{'id':0x2,'text':_0x2370d7(0x1d6)},{'id':0x3,'text':'Pembrolizumab'},{'id':0x4,'text':'Atezolimumab'}],'correct_choice_id':0x3,'solution':'<p><strong>Pembrolizumab</strong>\x20is\x20the\x20drug\x20recently\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>colorectal\x20cancer</strong>\x20arising\x20through\x20Lynch\x20syndrome.&nbsp;<span\x20class=\x22ILfuVd\x22>The\x20increased\x20risk\x20for\x20colorectal\x20cancer\x20in\x20Lynch\x20Syndrome\x20is\x20due\x20to\x20inherited\x20<strong>mutations</strong>\x20that\x20impair\x20<strong>DNA\x20mismatch\x20repair.</strong></span></p>\x0a<p>Immune\x20checkpoint\x20inhibitors\x20inhibit\x20proteins\x20that\x20help\x20to\x20keep\x20immune\x20responses\x20to\x20cancer\x20cells\x20in\x20check.\x20When\x20these\x20proteins\x20are\x20blocked,\x20the\x20brake\x20on\x20the\x20immune\x20system\x20is\x20released\x20and\x20T\x20cells\x20are\x20able\x20to\x20kill\x20cancer\x20cells\x20more\x20efficiently.</p>\x0a<p>Pembrolizumab\x20is\x20an\x20<strong>immune\x20checkpoint\x20inhibitor</strong>.\x20It\x20is\x20a\x20humanized\x20monoclonal\x20IgG4-<span\x20class=\x22ILfuVd\x22>&kappa;\x20isotype\x20antibody\x20that\x20blocks\x20the\x20interaction\x20between\x20programmed\x20cell\x20death\x20protein\x20(PD-1)\x20and\x20its\x20ligands.</span></p>\x0a<p>The\x20FDA\x20has\x20approved\x20pembrolizumab\x20for\x20patients\x20with\x20recurrent,\x20locally\x20advanced\x20or\x20metastatic,\x20squamous\x20cell\x20carcinoma\x20of\x20the\x20esophagus&nbsp;and\x20head\x20and\x20neck\x20squamous\x20cell\x20cancer\x20in\x20combination\x20with\x20platin\x20agents\x20and\x205-FU\x20for\x20the\x20first-line\x20treatment.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Pembrolizumab\x20is\x20not\x20approved\x20for\x20use\x20in\x20which\x20of\x20the\x20following\x20malignancies?','choices':[{'id':0x1,'text':'Non-metastatic\x20small\x20cell\x20lung\x20cancer'},{'id':0x2,'text':_0x2370d7(0x3c0)},{'id':0x3,'text':_0x2370d7(0x1b2)},{'id':0x4,'text':_0x2370d7(0x33a)}],'correct_choice_id':0x1,'solution':_0x2370d7(0x20c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x1d7),'choices':[{'id':0x1,'text':_0x2370d7(0x1ef)},{'id':0x2,'text':_0x2370d7(0x24d)},{'id':0x3,'text':_0x2370d7(0x1d5)},{'id':0x4,'text':'Atezolimumab'}],'correct_choice_id':0x3,'solution':'<p><strong>Reslizumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20<strong>against\x20interleukin-5</strong>\x20that\x20is\x20approved\x20for\x20use\x20in\x20<strong>severe</strong>&nbsp;<strong>asthma.</strong></p>\x0a<p>Option\x20A\x20&amp;\x20B:\x20Omalizumab\x20is\x20an\x20anti-IgE\x20antibody\x20and\x20lebrikizumab\x20is\x20an\x20antibody\x20against\x20interleukin\x2013,\x20which\x20are\x20also\x20indicated\x20in\x20the\x20management\x20of\x20asthma.</p>\x0a<p>Option\x20D:\x20Atezolizumab\x20is\x20an\x20immune\x20checkpoint\x20modulator\x20that\x20inhibits\x20the\x20interaction\x20of\x20PD-L1\x20with\x20PD-1\x20and\x20B7-H1.\x20It\x20is\x20approved\x20for\x20use\x20in\x20metastatic\x20urothelial\x20cancer\x20and\x20for\x20NSCLC.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x3af),'choices':[{'id':0x1,'text':_0x2370d7(0x236)},{'id':0x2,'text':_0x2370d7(0x1ef)},{'id':0x3,'text':_0x2370d7(0x2af)},{'id':0x4,'text':_0x2370d7(0x34b)}],'correct_choice_id':0x3,'solution':'<p><strong>Obiltoxaximab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20<strong>against</strong>\x20the\x20protective\x20antigen\x20of<strong>\x20<em>Bacillus\x20anthracis</em>.</strong></p>\x0a<p>It\x20is\x20indicated\x20in\x20the\x20<strong>treatment</strong>\x20of\x20<strong>inhalational\x20anthrax</strong>\x20due\x20to\x20<em>B.\x20anthracis</em>\x20in\x20combination\x20with\x20appropriate\x20antibacterial\x20drugs.\x20It\x20is\x20also\x20indicated\x20for\x20<strong>prophylaxis</strong>\x20of\x20inhalational\x20anthrax.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x3b7),'choices':[{'id':0x1,'text':_0x2370d7(0x236)},{'id':0x2,'text':_0x2370d7(0x271)},{'id':0x3,'text':_0x2370d7(0x3cd)},{'id':0x4,'text':_0x2370d7(0x34b)}],'correct_choice_id':0x3,'solution':_0x2370d7(0x26c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x2db),'choices':[{'id':0x1,'text':'Ruxolitinib'},{'id':0x2,'text':_0x2370d7(0x2f4)},{'id':0x3,'text':_0x2370d7(0x2ef)},{'id':0x4,'text':_0x2370d7(0x278)}],'correct_choice_id':0x2,'solution':'<p\x20style=\x22text-align:\x20justify;\x22><strong>Baricitinib</strong>\x20is\x20a<strong>\x20Janus\x20kinase\x20inhibitor</strong>\x20approved\x20for\x20use\x20in\x20<strong>rheumatoid\x20arthritis</strong>.&nbsp;</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Oral\x20Janus\x20kinase\x20inhibitors\x20for\x20rheumatoid\x20arthritis\x20are:</p>\x0a<ul\x20style=\x22text-align:\x20justify;\x22>\x0a<li>Baricitinib&nbsp;</li>\x0a<li>Tofacitinib&nbsp;</li>\x0a</ul>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Option\x20A:\x20<strong>Ruxolitinib</strong>\x20is\x20a\x20<strong>Janus\x20kinase\x20inhibitor</strong>\x20approved\x20for\x20use\x20in\x20various\x20forms\x20of\x20<strong>myelofibrosis</strong>,\x20<strong>polycythemia\x20vera</strong>\x20and\x20acute\x20graft\x20vs\x20host\x20disease.</p>\x0a<p\x20style=\x22text-align:\x20justify;\x22>Options\x20C\x20and\x20D:\x20Dasatinib\x20and\x20ponatinib\x20are\x20<strong>BCR-ABL\x20tyrosine\x20kinase\x20inhibitors</strong>\x20indicated\x20for\x20CML.&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x2d1),'choices':[{'id':0x1,'text':_0x2370d7(0x387)},{'id':0x2,'text':_0x2370d7(0x355)},{'id':0x3,'text':_0x2370d7(0x1f3)},{'id':0x4,'text':_0x2370d7(0x2d8)}],'correct_choice_id':0x4,'solution':_0x2370d7(0x314),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2370d7(0x26d),'choices':[{'id':0x1,'text':_0x2370d7(0x27a)},{'id':0x2,'text':'Moderate\x20atopic\x20dermatitis'},{'id':0x3,'text':_0x2370d7(0x2b8)},{'id':0x4,'text':_0x2370d7(0x2f5)}],'correct_choice_id':0x2,'solution':'<p\x20style=\x22text-align:\x20left;\x22><strong>Dupilumab\x20</strong>is\x20indicated\x20in\x20the\x20treatment\x20of\x20<strong>moderate</strong>-to-severe<strong>\x20atopic\x20dermatitis.&nbsp;</strong></p>\x0a<p\x20style=\x22text-align:\x20left;\x22>Dupilumab\x20<strong>inhibits</strong>\x20interleukins<strong>\x20IL-4</strong>\x20and\x20<strong>IL-13</strong>.\x20When\x20these\x20interleukins\x20are\x20inhibited,\x20they\x20are\x20unable\x20to\x20form\x20complexes\x20with\x20their\x20receptors.\x20This\x20results\x20in\x20a\x20decrease\x20in\x20the\x20immune\x20response&nbsp;including\x20the\x20release\x20of\x20proinflammatory\x20cytokines,\x20chemokines,\x20and\x20IgE.</p>','explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x2370d7(0x1b9);const quizFilename=_0x2370d7(0x42b);let hierarchy=['Marrow',_0x2370d7(0x1b7),_0x2370d7(0x386)];if(window[_0x2370d7(0x3bb)][_0x2370d7(0x382)][_0x2370d7(0x2b6)]('custom_quiz.html')){const customData=JSON[_0x2370d7(0x267)](localStorage[_0x2370d7(0x2cd)](_0x2370d7(0x2e1)));if(customData){const kHvUyq=_0x2370d7(0x1bc)[_0x2370d7(0x1e6)]('|');let iDSMaO=0x0;while(!![]){switch(kHvUyq[iDSMaO++]){case'0':document[_0x2370d7(0x398)](_0x2370d7(0x36e))[_0x2370d7(0x224)]=questionsData[_0x2370d7(0x1cd)];continue;case'1':hierarchy=customData[_0x2370d7(0x42a)];continue;case'2':questionsData=customData[_0x2370d7(0x378)];continue;case'3':document['title']=quizName+_0x2370d7(0x37b);continue;case'4':document[_0x2370d7(0x398)](_0x2370d7(0x3ba))[_0x2370d7(0x224)]=hierarchy['join']('\x20>\x20');continue;case'5':quizName=customData[_0x2370d7(0x227)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x2370d7(0x3c3),timer=null,timeRemaining=0x0,questionStartTime=Date['now'](),quizStartTime=Date[_0x2370d7(0x2b3)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x2370d7(0x1cd)])[_0x2370d7(0x23f)](null)[_0x2370d7(0x3e5)](()=>({'status':_0x2370d7(0x2c2),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData['length']};function saveProgress(){const _0x423f32=_0x2370d7,_0x59bd02={'trGHq':_0x423f32(0x1ed)};if(isQuizCompleted)return;const _0x45670a=JSON[_0x423f32(0x267)](localStorage['getItem'](_0x423f32(0x1ed)))||{};_0x45670a[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x423f32(0x3b4),'lastSeen':new Date()[_0x423f32(0x289)]()},localStorage[_0x423f32(0x34f)](_0x59bd02[_0x423f32(0x1ec)],JSON[_0x423f32(0x297)](_0x45670a));}function _0x407a(_0x12f467,_0x32cf3c){const _0xac27f6=_0x29a0();return _0x407a=function(_0x3758e3,_0xd7cd15){_0x3758e3=_0x3758e3-0x19e;let _0x568786=_0xac27f6[_0x3758e3];return _0x568786;},_0x407a(_0x12f467,_0x32cf3c);}function loadProgress(){const _0x3f4ca5=_0x2370d7,_0x285d15={'sWPcf':_0x3f4ca5(0x1ed),'ZWqpN':_0x3f4ca5(0x3f7)},_0x3dd858=JSON[_0x3f4ca5(0x267)](localStorage[_0x3f4ca5(0x2cd)](_0x285d15[_0x3f4ca5(0x1ab)]))||{},_0x78559f=_0x3dd858[quizFilename];if(_0x78559f){const _0x4d15c7=_0x285d15[_0x3f4ca5(0x213)]['split']('|');let _0x196180=0x0;while(!![]){switch(_0x4d15c7[_0x196180++]){case'0':questionStates=_0x78559f[_0x3f4ca5(0x3ef)];continue;case'1':currentMode=_0x78559f[_0x3f4ca5(0x31c)];continue;case'2':currentQuestionIndex=_0x78559f[_0x3f4ca5(0x416)];continue;case'3':return!![];case'4':stats=_0x78559f[_0x3f4ca5(0x328)];continue;case'5':console[_0x3f4ca5(0x1d9)](_0x3f4ca5(0x212));continue;}break;}}return![];}function clearProgress(){const _0x478d12=_0x2370d7,_0x3a5443={'yKtZV':_0x478d12(0x1ed)},_0x291c5f=JSON[_0x478d12(0x267)](localStorage[_0x478d12(0x2cd)](_0x3a5443[_0x478d12(0x2f9)]))||{};_0x291c5f[quizFilename]&&(delete _0x291c5f[quizFilename],localStorage[_0x478d12(0x34f)](_0x3a5443[_0x478d12(0x2f9)],JSON['stringify'](_0x291c5f)),console[_0x478d12(0x1d9)](_0x478d12(0x3ac)));}function markQuizAsCompleted(){const _0x3d99d5=_0x2370d7,_0x39b365={'qUnyf':_0x3d99d5(0x1ed),'enBGs':'completed'},_0x48f24a=JSON['parse'](localStorage['getItem'](_0x39b365['qUnyf']))||{},_0x34573b=questionsData['length'],_0x3d5708=stats['correctAnswers']||0x0;_0x48f24a[quizFilename]={'score':_0x3d5708,'total':_0x34573b,'status':_0x39b365['enBGs'],'completedOn':new Date()['toISOString']()},localStorage['setItem']('userHistory',JSON[_0x3d99d5(0x297)](_0x48f24a));}const urlParams=new URLSearchParams(window[_0x2370d7(0x3bb)]['search']),startAt=parseInt(urlParams[_0x2370d7(0x3dd)](_0x2370d7(0x38e))),resume=urlParams[_0x2370d7(0x3dd)](_0x2370d7(0x2bc))===_0x2370d7(0x285);function goBack(){const _0x506895=_0x2370d7,_0x18e649={'CdwGG':_0x506895(0x24c)};if(!isQuizCompleted)saveProgress();window[_0x506895(0x3bb)][_0x506895(0x35f)]=document[_0x506895(0x1d3)]||_0x18e649[_0x506895(0x2f7)];}function selectMode(_0x340cbb){const _0x2762ef=_0x2370d7,_0x4c35af={'PpAaA':'modeModal','pyGgc':_0x2762ef(0x3a7),'rSADo':function(_0x4e8e99){return _0x4e8e99();}};currentMode=_0x340cbb,document[_0x2762ef(0x398)](_0x4c35af[_0x2762ef(0x3ec)])[_0x2762ef(0x3c1)]['display']=_0x4c35af['pyGgc'],_0x4c35af['rSADo'](initializeQuiz);}function initializeQuiz(){const _0x4fad71=_0x2370d7,_0x512cd6={'lvQxv':_0x4fad71(0x22f),'VUDxT':'markReviewBtn','saaKs':_0x4fad71(0x250),'gBTOh':function(_0x1f7ce4,_0x125f21){return _0x1f7ce4===_0x125f21;},'xFBGu':_0x4fad71(0x3f8),'foAej':'none','xnXGA':_0x4fad71(0x215),'rOLjO':'testModeLegend','sZGfZ':_0x4fad71(0x217),'lGsWu':function(_0x2649df,_0x3f84f5){return _0x2649df===_0x3f84f5;},'tbuir':function(_0x5a1a3a,_0x3ac901){return _0x5a1a3a===_0x3ac901;},'RrvqG':_0x4fad71(0x408),'GvesJ':function(_0x3afa2e,_0x317d68){return _0x3afa2e(_0x317d68);},'JmFxY':function(_0x1404b5,_0x96e242){return _0x1404b5>=_0x96e242;},'hvUuC':function(_0x4e9ddc,_0x1e9609){return _0x4e9ddc<_0x1e9609;},'Merwi':function(_0x3ec5b2){return _0x3ec5b2();}};quizStartTime=Date[_0x4fad71(0x2b3)]();const _0x1bba71=document[_0x4fad71(0x398)](_0x512cd6[_0x4fad71(0x28b)]),_0x55cdb1=document[_0x4fad71(0x398)](_0x512cd6['VUDxT']),_0x1637ec=document['getElementById'](_0x512cd6[_0x4fad71(0x32e)]),_0xeaf66e=_0x512cd6['gBTOh'](currentMode,_0x512cd6[_0x4fad71(0x427)])||_0x512cd6[_0x4fad71(0x33e)](currentMode,_0x4fad71(0x408));document[_0x4fad71(0x398)]('statsBar')[_0x4fad71(0x3c1)][_0x4fad71(0x350)]=_0xeaf66e?_0x512cd6[_0x4fad71(0x23d)]:_0x512cd6['xnXGA'],document['getElementById']('studyModeLegend')[_0x4fad71(0x3c1)]['display']=_0xeaf66e?_0x512cd6[_0x4fad71(0x23d)]:_0x4fad71(0x215),document[_0x4fad71(0x398)](_0x512cd6[_0x4fad71(0x3e8)])['style']['display']=_0xeaf66e?_0x512cd6[_0x4fad71(0x372)]:_0x512cd6[_0x4fad71(0x23d)],document[_0x4fad71(0x398)](_0x4fad71(0x35a))[_0x4fad71(0x3c1)]['display']=_0xeaf66e?_0x4fad71(0x215):_0x512cd6[_0x4fad71(0x23d)],_0x1bba71[_0x4fad71(0x3c1)][_0x4fad71(0x350)]=_0xeaf66e?_0x512cd6[_0x4fad71(0x23d)]:_0x512cd6[_0x4fad71(0x1c7)],_0x55cdb1[_0x4fad71(0x3c1)]['display']=_0xeaf66e?'flex':_0x512cd6[_0x4fad71(0x23d)],_0x1637ec['style'][_0x4fad71(0x350)]=_0xeaf66e?_0x512cd6['sZGfZ']:_0x4fad71(0x3a7),(_0x512cd6[_0x4fad71(0x2f2)](currentMode,_0x4fad71(0x251))||_0x512cd6[_0x4fad71(0x2c6)](currentMode,_0x512cd6['RrvqG']))&&document['getElementById'](_0x4fad71(0x2fb))['classList'][_0x4fad71(0x320)]('hidden'),!_0x512cd6[_0x4fad71(0x24f)](isNaN,startAt)&&_0x512cd6['JmFxY'](startAt,0x0)&&_0x512cd6[_0x4fad71(0x3ad)](startAt,questionsData['length'])&&(currentQuestionIndex=startAt),_0x512cd6[_0x4fad71(0x366)](loadBookmarkedQuestions),generateQuestionNav(),_0x512cd6[_0x4fad71(0x366)](updateStats),_0x512cd6['Merwi'](displayQuestion);}function generateQuestionNav(){const _0x4720d4=_0x2370d7,_0x49b727={'imtxS':_0x4720d4(0x32f),'FQBtP':function(_0x31d3c3,_0x4702a4){return _0x31d3c3<_0x4702a4;},'WpgEd':_0x4720d4(0x1f8),'WOlxz':function(_0x32494d,_0x2a16f1){return _0x32494d+_0x2a16f1;},'WOmoZ':_0x4720d4(0x323),'AwqYm':function(_0xb18680){return _0xb18680();}},_0x137ead=document[_0x4720d4(0x398)](_0x49b727[_0x4720d4(0x1e7)]);_0x137ead[_0x4720d4(0x2a2)]='';for(let _0x542e9a=0x0;_0x49b727['FQBtP'](_0x542e9a,questionsData[_0x4720d4(0x1cd)]);_0x542e9a++){const _0x14209a=document[_0x4720d4(0x3a0)](_0x49b727[_0x4720d4(0x20a)]);_0x14209a[_0x4720d4(0x224)]=_0x49b727[_0x4720d4(0x3ae)](_0x542e9a,0x1),_0x14209a[_0x4720d4(0x3e7)]=_0x49b727[_0x4720d4(0x27d)],_0x14209a['onclick']=()=>jumpToQuestion(_0x542e9a),_0x14209a['id']='navBtn_'+_0x542e9a,_0x137ead[_0x4720d4(0x41a)](_0x14209a);}_0x49b727[_0x4720d4(0x337)](updateQuestionNav);}function updateQuestionNav(){const _0x39ece2=_0x2370d7,_0x18d01d={'ixCgO':function(_0x5b4c01,_0x4b7431){return _0x5b4c01===_0x4b7431;},'aMkwq':function(_0x2fa4e4){return _0x2fa4e4();},'kYBTt':'none','TYvBB':_0x39ece2(0x30e),'nBzbp':_0x39ece2(0x217),'AKUlP':function(_0x48a3fd,_0x214ae7){return _0x48a3fd<_0x214ae7;},'JEVkc':function(_0x126ded,_0x51780e){return _0x126ded===_0x51780e;},'hicVp':'nav-btn-current','ofbuK':function(_0x370225,_0x450c9d){return _0x370225!==_0x450c9d;},'MfyGK':_0x39ece2(0x316),'EdTnJ':_0x39ece2(0x1fd),'wiFSF':'nav-btn-bookmarked','jXMkG':_0x39ece2(0x42c),'aLGbb':_0x39ece2(0x3c3),'xoSeQ':function(_0x54c95c,_0x1a5866){return _0x54c95c===_0x1a5866;},'QOEBn':_0x39ece2(0x232),'Irnkg':_0x39ece2(0x3a8),'RnOdX':_0x39ece2(0x2a0),'EuqBq':_0x39ece2(0x2ad),'QvFdM':function(_0x5df715,_0x16b389){return _0x5df715!==_0x16b389;},'zfLDD':'GgaIj','wVAAc':'nav-btn-answered'};for(let _0x3916ad=0x0;_0x18d01d['AKUlP'](_0x3916ad,questionsData['length']);_0x3916ad++){const _0x4bb165=document['getElementById'](_0x39ece2(0x28f)+_0x3916ad),_0x2841a1=questionStates[_0x3916ad];let _0x2d99da='';if(_0x18d01d[_0x39ece2(0x36d)](_0x3916ad,currentQuestionIndex))_0x18d01d[_0x39ece2(0x36d)](_0x39ece2(0x2e0),_0x39ece2(0x2e0))?_0x2d99da=_0x18d01d['hicVp']:_0x18d01d[_0x39ece2(0x31f)](_0x5d221f[_0x39ece2(0x1da)][_0x23ac15[_0x39ece2(0x313)]]['id'],_0x4a2df4[_0x39ece2(0x28d)])?(_0x1fa7bf++,_0x17b260[_0x39ece2(0x2d2)]='correct'):(_0x149812++,_0x3edbd1[_0x39ece2(0x2d2)]=_0x39ece2(0x209));else{if(_0x2841a1['bookmarked'])_0x18d01d['ofbuK'](_0x18d01d[_0x39ece2(0x1d8)],_0x18d01d[_0x39ece2(0x379)])?_0x2d99da=_0x18d01d[_0x39ece2(0x322)]:_0x45cb00['src']=_0x3deffc;else{if(_0x2841a1['markedForReview'])_0x2d99da=_0x18d01d[_0x39ece2(0x32a)];else{if(currentMode===_0x18d01d[_0x39ece2(0x31a)]||_0x18d01d[_0x39ece2(0x31f)](currentMode,_0x39ece2(0x251))){if(_0x18d01d[_0x39ece2(0x245)](_0x2841a1[_0x39ece2(0x2d2)],_0x18d01d[_0x39ece2(0x333)]))_0x2d99da=_0x18d01d['Irnkg'];else{if(_0x18d01d[_0x39ece2(0x31f)](_0x2841a1[_0x39ece2(0x2d2)],_0x39ece2(0x209)))_0x2d99da=_0x18d01d[_0x39ece2(0x1ac)];else _0x2d99da=_0x18d01d[_0x39ece2(0x3bc)];}}else{if(_0x18d01d[_0x39ece2(0x233)](_0x18d01d[_0x39ece2(0x275)],'UDAAa')){if(_0x18d01d['QvFdM'](_0x2841a1['selectedAnswer'],null))_0x2d99da=_0x18d01d[_0x39ece2(0x426)];else _0x2d99da=_0x18d01d[_0x39ece2(0x3bc)];}else _0x18d01d[_0x39ece2(0x30b)](_0x4fda3c)?(_0x5e029a[_0x39ece2(0x398)](_0x39ece2(0x30e))['style'][_0x39ece2(0x350)]=_0x18d01d['kYBTt'],_0x18d01d['aMkwq'](_0x1a0044)):(_0x18d01d[_0x39ece2(0x30b)](_0x1e971e),_0x10bfdd[_0x39ece2(0x398)](_0x18d01d['TYvBB'])[_0x39ece2(0x3c1)][_0x39ece2(0x350)]=_0x18d01d['nBzbp']);}}}}_0x4bb165[_0x39ece2(0x3e7)]=_0x39ece2(0x38f)+_0x2d99da;}}function jumpToQuestion(_0x44ca9b){const _0x590204=_0x2370d7,_0x16097b={'odeRs':_0x590204(0x209),'wcWPZ':function(_0x1b3d7f,_0x2ef509){return _0x1b3d7f>=_0x2ef509;},'tXXsE':function(_0x169a30,_0x4e54bc){return _0x169a30<_0x4e54bc;},'WppFz':function(_0x2d5e64,_0x273418){return _0x2d5e64===_0x273418;},'TaJrp':_0x590204(0x252),'NXNnB':function(_0x1ef3a2,_0x4a4bdd){return _0x1ef3a2-_0x4a4bdd;},'qRhzO':function(_0x53eb4c){return _0x53eb4c();}};_0x16097b[_0x590204(0x207)](_0x44ca9b,0x0)&&_0x16097b[_0x590204(0x340)](_0x44ca9b,questionsData[_0x590204(0x1cd)])&&(_0x16097b[_0x590204(0x261)](_0x590204(0x339),_0x16097b[_0x590204(0x2a4)])?(_0x15c774++,_0x1d1a36[_0x590204(0x2d2)]=_0x16097b['odeRs']):(questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x16097b[_0x590204(0x336)](Date['now'](),questionStartTime)),currentQuestionIndex=_0x44ca9b,_0x16097b[_0x590204(0x2fc)](displayQuestion),_0x16097b['qRhzO'](saveProgress)));}function updateStats(){const _0x5a829a=_0x2370d7,_0x3f204c={'faVcf':function(_0x3664eb,_0x1f0a97){return _0x3664eb===_0x1f0a97;},'yKjnX':_0x5a829a(0x251),'BMTEO':_0x5a829a(0x1be),'EcBIU':_0x5a829a(0x341),'zWgJL':function(_0x12d18c,_0x10cae0){return _0x12d18c>_0x10cae0;},'PzDgE':function(_0x2916b7,_0x542540){return _0x2916b7*_0x542540;},'HlfDt':function(_0x4acfd8,_0x323ca1){return _0x4acfd8/_0x323ca1;},'MIfZa':_0x5a829a(0x368),'JDBmh':function(_0x3c009c,_0x52ab4c){return _0x3c009c%_0x52ab4c;},'ujTYR':_0x5a829a(0x422),'IFqyO':function(_0x3efdfd,_0x325c98){return _0x3efdfd+_0x325c98;}};if(currentMode==='study'||_0x3f204c['faVcf'](currentMode,_0x3f204c[_0x5a829a(0x373)])){document[_0x5a829a(0x398)](_0x5a829a(0x2eb))['textContent']=stats[_0x5a829a(0x385)],document[_0x5a829a(0x398)](_0x3f204c['BMTEO'])[_0x5a829a(0x224)]=stats[_0x5a829a(0x3c2)],document[_0x5a829a(0x398)](_0x3f204c[_0x5a829a(0x2a3)])[_0x5a829a(0x224)]=stats[_0x5a829a(0x341)];const _0x1c20a1=_0x3f204c[_0x5a829a(0x204)](stats[_0x5a829a(0x341)],0x0)?Math[_0x5a829a(0x1db)](_0x3f204c[_0x5a829a(0x2c8)](_0x3f204c[_0x5a829a(0x331)](stats['correctAnswers'],stats['totalAttempted']),0x64)):0x0;document[_0x5a829a(0x398)](_0x3f204c[_0x5a829a(0x2b4)])[_0x5a829a(0x224)]=_0x1c20a1+'%',stats[_0x5a829a(0x1bb)]=questionStates[_0x5a829a(0x329)]((_0xe17a1b,_0x525c80)=>_0xe17a1b+_0x525c80[_0x5a829a(0x422)],0x0);const _0x3b4016=Math[_0x5a829a(0x399)](_0x3f204c[_0x5a829a(0x331)](stats[_0x5a829a(0x1bb)],0x3e8)),_0xf4d6fa=Math[_0x5a829a(0x399)](_0x3f204c[_0x5a829a(0x331)](_0x3b4016,0x3c)),_0x2e2ebe=_0x3f204c[_0x5a829a(0x1ca)](_0x3b4016,0x3c);document[_0x5a829a(0x398)](_0x3f204c['ujTYR'])[_0x5a829a(0x224)]=_0x3f204c['IFqyO'](_0xf4d6fa,':')+_0x2e2ebe[_0x5a829a(0x2dd)]()['padStart'](0x2,'0');}}function setupVideo(_0x4ff82e,_0x1b279b){const _0x460d62=_0x2370d7;if(Hls['isSupported']()){const _0x4b5dfd=new Hls();_0x4b5dfd[_0x460d62(0x272)](_0x1b279b),_0x4b5dfd['attachMedia'](_0x4ff82e);}else _0x4ff82e[_0x460d62(0x1e9)](_0x460d62(0x349))&&(_0x4ff82e['src']=_0x1b279b);}function displayQuestion(){const _0x3bc15d=_0x2370d7,_0x454a17={'WWqou':_0x3bc15d(0x1c5),'idivc':_0x3bc15d(0x40a),'pVidy':function(_0x38a8f8,_0x4cf4c5){return _0x38a8f8===_0x4cf4c5;},'UCVty':'div','nqZkD':'selected','Icyvz':function(_0x453a41,_0x2c1819){return _0x453a41+_0x2c1819;},'vmQAU':'Option\x20','HKqhj':function(_0x13c0ad,_0x4f21d4){return _0x13c0ad+_0x4f21d4;},'cnmpT':_0x3bc15d(0x1be),'jKsnY':function(_0x67ebfc,_0x4a43c6){return _0x67ebfc>_0x4a43c6;},'WwTeC':function(_0x54bf37,_0x283990){return _0x54bf37/_0x283990;},'gMsVo':_0x3bc15d(0x368),'MwcNI':function(_0x2b3252,_0x3ab201){return _0x2b3252/_0x3ab201;},'NeSAe':function(_0x18728c,_0x5e3135){return _0x18728c%_0x5e3135;},'umDYi':_0x3bc15d(0x422),'DXQNz':function(_0x2d7fc5,_0x976020){return _0x2d7fc5+_0x976020;},'ClxeZ':_0x3bc15d(0x3f0),'szrrg':_0x3bc15d(0x2df),'YUXPT':function(_0x100251,_0x1460d2){return _0x100251(_0x1460d2);},'OauCc':_0x3bc15d(0x35d),'SwHpV':function(_0x301cc5,_0x1210d8){return _0x301cc5(_0x1210d8);},'xarzB':_0x3bc15d(0x24b),'fGcdZ':'progressBar','xLbuj':_0x3bc15d(0x3f2),'qlRsF':_0x3bc15d(0x418),'gOCtM':function(_0x9e3f0b,_0x243a6a){return _0x9e3f0b===_0x243a6a;},'jttmf':_0x3bc15d(0x362),'ZHbZa':_0x3bc15d(0x34d),'JQRRh':'No\x20question\x20text\x20available','oNrFe':_0x3bc15d(0x1a8),'XVjno':_0x3bc15d(0x412),'fRPIy':_0x3bc15d(0x25a),'xODUw':function(_0x5952e9){return _0x5952e9();},'HtAFD':function(_0x13b845,_0x37c556){return _0x13b845===_0x37c556;},'Cllwz':_0x3bc15d(0x251),'auAds':function(_0x11356a,_0x5af82f){return _0x11356a===_0x5af82f;},'cMgwM':_0x3bc15d(0x408)};if(!questionsData||_0x454a17[_0x3bc15d(0x2e2)](questionsData[_0x3bc15d(0x1cd)],0x0)){document['getElementById'](_0x454a17['xarzB'])['innerHTML']='No\x20questions\x20available\x20for\x20this\x20quiz.';return;};const _0x294e20=questionsData[currentQuestionIndex];questionStartTime=Date[_0x3bc15d(0x2b3)](),selectedOption=questionStates[currentQuestionIndex][_0x3bc15d(0x313)];const _0x15630a=_0x454a17['WwTeC'](_0x454a17[_0x3bc15d(0x3df)](currentQuestionIndex,0x1),questionsData['length'])*0x64;document['getElementById'](_0x454a17[_0x3bc15d(0x410)])['style']['width']=_0x454a17[_0x3bc15d(0x265)](_0x15630a,'%'),document[_0x3bc15d(0x398)](_0x454a17['xLbuj'])[_0x3bc15d(0x224)]=currentQuestionIndex+0x1,updateQuestionNav(),document[_0x3bc15d(0x398)](_0x454a17[_0x3bc15d(0x25d)])['disabled']=_0x454a17[_0x3bc15d(0x230)](currentQuestionIndex,0x0),document['getElementById'](_0x454a17[_0x3bc15d(0x3c5)])[_0x3bc15d(0x35b)][_0x3bc15d(0x3c6)](_0x454a17[_0x3bc15d(0x2bf)]),document[_0x3bc15d(0x398)]('questionText')[_0x3bc15d(0x2a2)]=_0x294e20[_0x3bc15d(0x35c)]||_0x454a17[_0x3bc15d(0x3b2)];let _0x3eb76e='';if(_0x294e20[_0x3bc15d(0x30d)])_0x3eb76e+=_0x3bc15d(0x22e)+_0x294e20[_0x3bc15d(0x30d)]+_0x3bc15d(0x34a);if(_0x294e20[_0x3bc15d(0x211)])_0x3eb76e+=_0x3bc15d(0x253)+_0x294e20[_0x3bc15d(0x211)]+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x294e20[_0x3bc15d(0x2fe)]&&_0x294e20['question_images']['forEach'](_0x540be1=>{const _0x33dac6=_0x3bc15d,_0x49dfab={'vHWDn':_0x454a17['WWqou']};if(_0x454a17[_0x33dac6(0x21c)]!==_0x454a17[_0x33dac6(0x21c)])_0x5dbceb[_0x54e6ce][_0x33dac6(0x2d2)]=_0x49dfab[_0x33dac6(0x302)],_0x4216ed[_0x33dac6(0x341)]++,_0x56da5e[_0x33dac6(0x279)]--;else{if(_0x540be1)_0x3eb76e+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x540be1+_0x33dac6(0x30a);}});document[_0x3bc15d(0x398)](_0x454a17[_0x3bc15d(0x360)])[_0x3bc15d(0x2a2)]=_0x3eb76e;const _0x4741eb=document[_0x3bc15d(0x398)](_0x454a17[_0x3bc15d(0x359)]);_0x4741eb['innerHTML']='',_0x4741eb[_0x3bc15d(0x35b)][_0x3bc15d(0x320)](_0x454a17[_0x3bc15d(0x3e9)]),_0x294e20[_0x3bc15d(0x1da)]&&Array[_0x3bc15d(0x35e)](_0x294e20[_0x3bc15d(0x1da)])&&(_0x294e20['choices'][_0x3bc15d(0x1dc)]((_0x470761,_0x131691)=>{const _0xb73c7f=_0x3bc15d,_0x300d0e=String[_0xb73c7f(0x401)](0x41+_0x131691),_0x10aaba=_0x454a17[_0xb73c7f(0x2e2)](selectedOption,_0x131691),_0x3b26b3=document[_0xb73c7f(0x3a0)](_0x454a17['UCVty']);_0x3b26b3['innerHTML']=_0xb73c7f(0x39d)+(_0x10aaba?_0x454a17[_0xb73c7f(0x219)]:'')+_0xb73c7f(0x36f)+_0x131691+_0xb73c7f(0x255)+_0x300d0e+_0xb73c7f(0x40f)+(_0x470761['text']||_0x454a17['Icyvz'](_0x454a17[_0xb73c7f(0x19f)],_0x454a17[_0xb73c7f(0x3df)](_0x131691,0x1)))+_0xb73c7f(0x1bd),_0x4741eb['appendChild'](_0x3b26b3);}),_0x4741eb['addEventListener'](_0x454a17[_0x3bc15d(0x2e4)],function(_0x4e3ca0){const _0x8d71cd=_0x3bc15d,_0x41c5d6=_0x4e3ca0['target']['closest'](_0x454a17[_0x8d71cd(0x2be)]);if(_0x41c5d6){if(_0x454a17[_0x8d71cd(0x2e2)](_0x454a17[_0x8d71cd(0x1b0)],_0x454a17[_0x8d71cd(0x1b0)])){const _0x31728f=_0x454a17[_0x8d71cd(0x2d5)](parseInt,_0x41c5d6['getAttribute'](_0x454a17[_0x8d71cd(0x26b)]));_0x454a17[_0x8d71cd(0x2b0)](selectOption,_0x31728f);}else{_0x159b41[_0x8d71cd(0x398)]('correctCount')[_0x8d71cd(0x224)]=_0x58b185[_0x8d71cd(0x385)],_0xc9ea0c[_0x8d71cd(0x398)](_0x454a17[_0x8d71cd(0x375)])[_0x8d71cd(0x224)]=_0x404ae6[_0x8d71cd(0x3c2)],_0x343ee9[_0x8d71cd(0x398)](_0x8d71cd(0x341))[_0x8d71cd(0x224)]=_0x4fa5f8[_0x8d71cd(0x341)];const _0x188da0=_0x454a17[_0x8d71cd(0x2a9)](_0x3054a7['totalAttempted'],0x0)?_0x10f92a[_0x8d71cd(0x1db)](_0x454a17[_0x8d71cd(0x22d)](_0x3b1c7a[_0x8d71cd(0x385)],_0xf060fe[_0x8d71cd(0x341)])*0x64):0x0;_0x51b1f2[_0x8d71cd(0x398)](_0x454a17[_0x8d71cd(0x38d)])[_0x8d71cd(0x224)]=_0x454a17[_0x8d71cd(0x3df)](_0x188da0,'%'),_0x39466f[_0x8d71cd(0x1bb)]=_0x45032d[_0x8d71cd(0x329)]((_0x2f6b29,_0x3e9c0d)=>_0x2f6b29+_0x3e9c0d['timeSpent'],0x0);const _0x38a408=_0x432de6[_0x8d71cd(0x399)](_0x572cc9[_0x8d71cd(0x1bb)]/0x3e8),_0x15fb79=_0x18fc75['floor'](_0x454a17[_0x8d71cd(0x1de)](_0x38a408,0x3c)),_0x815240=_0x454a17[_0x8d71cd(0x29a)](_0x38a408,0x3c);_0x465630[_0x8d71cd(0x398)](_0x454a17[_0x8d71cd(0x28c)])[_0x8d71cd(0x224)]=_0x454a17[_0x8d71cd(0x3df)](_0x454a17[_0x8d71cd(0x2e8)](_0x15fb79,':'),_0x815240[_0x8d71cd(0x2dd)]()[_0x8d71cd(0x1d2)](0x2,'0'));}}})),_0x454a17['xODUw'](updateBookmarkButton),_0x454a17[_0x3bc15d(0x2d7)](updateMarkReviewButton),(_0x454a17['HtAFD'](currentMode,_0x454a17['Cllwz'])||_0x454a17['auAds'](currentMode,_0x454a17['cMgwM']))&&!isQuizCompleted&&_0x454a17[_0x3bc15d(0x2d7)](startTimer);}function selectOption(_0x3eb6f3){const _0xf780e2=_0x2370d7,_0x25cc74={'ybScy':'selected','HIdhj':function(_0x59eea5,_0x393b45){return _0x59eea5===_0x393b45;},'BmPIM':'timed_study','AjDGA':'correctCount','UJZlj':_0xf780e2(0x341),'OCYAo':function(_0x1769f1,_0x1c82c5){return _0x1769f1>_0x1c82c5;},'epqEx':function(_0x1ed8b5,_0xc6c09){return _0x1ed8b5/_0xc6c09;},'IYZpg':_0xf780e2(0x368),'nBlmT':function(_0x4b300d,_0x222138){return _0x4b300d+_0x222138;},'dlydA':function(_0x52dba4,_0x123897){return _0x52dba4%_0x123897;},'flDOz':_0xf780e2(0x422),'XFAuy':function(_0x57135a,_0x58afbb){return _0x57135a+_0x58afbb;},'xrQQq':'optionsContainer','FIkpB':_0xf780e2(0x1c5),'hdIxn':_0xf780e2(0x3f0),'gKJMq':function(_0xc7ce34,_0x1c4e3e){return _0xc7ce34===_0x1c4e3e;},'WcLYz':function(_0x599c84,_0xd39eb0){return _0x599c84!==_0xd39eb0;},'VioEw':_0xf780e2(0x34c),'RszzW':function(_0x12422f){return _0x12422f();},'xYRXs':function(_0x237eb7){return _0x237eb7();}},_0x2390c7=document[_0xf780e2(0x398)](_0x25cc74[_0xf780e2(0x3b1)]);if(_0x2390c7[_0xf780e2(0x35b)]['contains'](_0x25cc74[_0xf780e2(0x20b)]))return;questionStartTime&&(questionStates[currentQuestionIndex][_0xf780e2(0x422)]+=Date[_0xf780e2(0x2b3)]()-questionStartTime,questionStartTime=Date[_0xf780e2(0x2b3)]());selectedOption=_0x3eb6f3,questionStates[currentQuestionIndex][_0xf780e2(0x313)]=_0x3eb6f3,document[_0xf780e2(0x3d5)](_0x25cc74[_0xf780e2(0x29b)])['forEach']((_0x5ccde0,_0x9ea14e)=>{const _0x402e1f=_0xf780e2;_0x5ccde0['classList']['toggle'](_0x25cc74[_0x402e1f(0x3c8)],_0x25cc74[_0x402e1f(0x262)](_0x9ea14e,_0x3eb6f3));});if(_0x25cc74['gKJMq'](currentMode,_0xf780e2(0x3c3))||_0x25cc74[_0xf780e2(0x1e8)](currentMode,_0x25cc74[_0xf780e2(0x22c)])){if(_0x25cc74[_0xf780e2(0x2c4)](_0x25cc74[_0xf780e2(0x334)],_0x25cc74['VioEw'])){if(_0x219f8a===_0xf780e2(0x3c3)||_0x287dd2===_0x25cc74[_0xf780e2(0x22c)]){_0x2d549f['getElementById'](_0x25cc74[_0xf780e2(0x421)])[_0xf780e2(0x224)]=_0x1e7193[_0xf780e2(0x385)],_0x26f7fb[_0xf780e2(0x398)](_0xf780e2(0x1be))[_0xf780e2(0x224)]=_0x481610[_0xf780e2(0x3c2)],_0x2eb082[_0xf780e2(0x398)](_0x25cc74[_0xf780e2(0x23b)])[_0xf780e2(0x224)]=_0x240230[_0xf780e2(0x341)];const _0x39a32c=_0x25cc74[_0xf780e2(0x24a)](_0x1a4fea[_0xf780e2(0x341)],0x0)?_0x121156['round'](_0x25cc74[_0xf780e2(0x1c0)](_0x474081[_0xf780e2(0x385)],_0x37cd12[_0xf780e2(0x341)])*0x64):0x0;_0x286bd9['getElementById'](_0x25cc74[_0xf780e2(0x39e)])[_0xf780e2(0x224)]=_0x25cc74[_0xf780e2(0x36c)](_0x39a32c,'%'),_0x296b78['totalTime']=_0xae4726['reduce']((_0x249119,_0x3648f9)=>_0x249119+_0x3648f9['timeSpent'],0x0);const _0x230170=_0x1620ca['floor'](_0x25cc74[_0xf780e2(0x1c0)](_0xf69a62[_0xf780e2(0x1bb)],0x3e8)),_0xa233c9=_0x1fb040[_0xf780e2(0x399)](_0x25cc74[_0xf780e2(0x1c0)](_0x230170,0x3c)),_0x3b8f6a=_0x25cc74['dlydA'](_0x230170,0x3c);_0xddff85['getElementById'](_0x25cc74[_0xf780e2(0x2e7)])['textContent']=_0x25cc74[_0xf780e2(0x36c)](_0x25cc74[_0xf780e2(0x3d6)](_0xa233c9,':'),_0x3b8f6a[_0xf780e2(0x2dd)]()['padStart'](0x2,'0'));}}else _0x25cc74['RszzW'](processAnswer);}else questionStates[currentQuestionIndex]['status']===_0xf780e2(0x2c2)&&(questionStates[currentQuestionIndex][_0xf780e2(0x2d2)]=_0x25cc74['FIkpB'],stats[_0xf780e2(0x341)]++,stats[_0xf780e2(0x279)]--),_0x25cc74[_0xf780e2(0x3be)](updateQuestionNav);_0x25cc74[_0xf780e2(0x390)](saveProgress);}function processAnswer(){const _0x2ffaf3=_0x2370d7,_0x4dc285={'bLkyU':function(_0x4d89a9,_0x5b8ad1){return _0x4d89a9===_0x5b8ad1;},'bRHBH':function(_0x265ee9,_0x4a9e3c){return _0x265ee9===_0x4a9e3c;},'uSdJh':_0x2ffaf3(0x2c2),'VPIXk':'btzCz','IZbXM':_0x2ffaf3(0x209),'MZMYu':function(_0x5ab7b4,_0x431c1c){return _0x5ab7b4(_0x431c1c);}},_0x2f1e84=questionsData[currentQuestionIndex],_0x40fcf7=_0x2f1e84[_0x2ffaf3(0x28d)];if(_0x4dc285[_0x2ffaf3(0x338)](selectedOption,null))return;const _0x4b1f9a=_0x2f1e84[_0x2ffaf3(0x1da)][selectedOption],_0x3137cc=_0x4dc285[_0x2ffaf3(0x338)](_0x4b1f9a['id'],_0x40fcf7);if(_0x4dc285[_0x2ffaf3(0x1e1)](questionStates[currentQuestionIndex]['status'],_0x4dc285[_0x2ffaf3(0x1bf)])){if(_0x4dc285[_0x2ffaf3(0x1fa)]===_0x4dc285[_0x2ffaf3(0x1fa)]){stats[_0x2ffaf3(0x341)]++,stats[_0x2ffaf3(0x279)]--;if(_0x3137cc)stats[_0x2ffaf3(0x385)]++;else stats[_0x2ffaf3(0x3c2)]++;}else{if(_0x315c61)_0x19a596+=_0x2ffaf3(0x3e0)+_0x166a03+_0x2ffaf3(0x30a);}}questionStates[currentQuestionIndex][_0x2ffaf3(0x2d2)]=_0x3137cc?_0x2ffaf3(0x232):_0x4dc285['IZbXM'],updateStats(),_0x4dc285[_0x2ffaf3(0x32d)](showInlineFeedback,_0x3137cc),updateQuestionNav();}function showInlineFeedback(_0x1438eb){const _0x137b18=_0x2370d7,_0x1619ce={'JWhFt':_0x137b18(0x1c2),'EfQKN':function(_0x5c354d,_0x2617b6){return _0x5c354d===_0x2617b6;},'bxtZu':_0x137b18(0x232),'lkniD':function(_0x46ef39,_0x4563a3){return _0x46ef39===_0x4563a3;},'xIjAc':_0x137b18(0x209),'EClRz':function(_0x46a7f2,_0xf53c12){return _0x46a7f2!==_0xf53c12;},'IDDXF':function(_0x74fbc0,_0x97238){return _0x74fbc0!==_0x97238;},'DzPSx':'timed_study','HxiNY':_0x137b18(0x412),'xXLsu':_0x137b18(0x3f0),'Xbpaz':function(_0x3dc9a6){return _0x3dc9a6();}};if(_0x1619ce[_0x137b18(0x376)](currentMode,_0x137b18(0x3c3))&&_0x1619ce[_0x137b18(0x226)](currentMode,_0x1619ce[_0x137b18(0x1dd)]))return;const _0x543669=document[_0x137b18(0x398)](_0x1619ce[_0x137b18(0x3a3)]),_0x4129a8=_0x543669['querySelectorAll'](_0x1619ce[_0x137b18(0x3d9)]),_0x181f90=questionsData[currentQuestionIndex],_0x42596d=_0x181f90[_0x137b18(0x28d)];let _0x369c0e=_0x181f90[_0x137b18(0x1da)][_0x137b18(0x248)](_0x1d5d98=>_0x1d5d98['id']===_0x42596d);_0x543669[_0x137b18(0x35b)]['add'](_0x137b18(0x1c5)),_0x4129a8['forEach']((_0x391a7c,_0x218184)=>{const _0x270c34=_0x137b18;_0x391a7c[_0x270c34(0x35b)][_0x270c34(0x320)](_0x1619ce[_0x270c34(0x27c)]);if(_0x1619ce[_0x270c34(0x330)](_0x218184,_0x369c0e))_0x391a7c['classList'][_0x270c34(0x3c6)](_0x1619ce[_0x270c34(0x38a)]);else{if(_0x1619ce[_0x270c34(0x270)](_0x218184,selectedOption)&&!_0x1438eb)_0x391a7c[_0x270c34(0x35b)]['add'](_0x1619ce[_0x270c34(0x414)]);}}),_0x1619ce[_0x137b18(0x238)](showSolution);}function showSolution(){const _0x2776d0=_0x2370d7,_0x2ef577={'DGBDd':_0x2776d0(0x22f),'YXTTq':_0x2776d0(0x259),'AnGSt':_0x2776d0(0x1ce),'pfsWI':_0x2776d0(0x1fb),'tbBhe':function(_0x3f149c,_0x468b12){return _0x3f149c!==_0x468b12;},'woNkE':_0x2776d0(0x251),'zMdyd':_0x2776d0(0x354),'oLcoU':_0x2776d0(0x424),'FYKVz':_0x2776d0(0x274),'jyfsH':'explanationVideoPlayer','jiFps':_0x2776d0(0x34d),'CTSCc':_0x2776d0(0x27b),'yDmYm':function(_0x328f09,_0x456bba,_0x55cc99){return _0x328f09(_0x456bba,_0x55cc99);},'RTRBq':_0x2776d0(0x33b),'cBgmo':_0x2776d0(0x3c7),'Veqyc':function(_0x34002f,_0x10f4e5){return _0x34002f===_0x10f4e5;},'bNEdV':'SaPCq'};if(_0x2ef577[_0x2776d0(0x428)](currentMode,_0x2776d0(0x3c3))&&_0x2ef577[_0x2776d0(0x428)](currentMode,_0x2ef577[_0x2776d0(0x2aa)]))return;const _0x5298d2=questionsData[currentQuestionIndex];document['getElementById'](_0x2ef577[_0x2776d0(0x21a)])[_0x2776d0(0x2a2)]=_0x5298d2[_0x2776d0(0x268)]||_0x2ef577['oLcoU'];const _0x480d11=document[_0x2776d0(0x398)](_0x2ef577[_0x2776d0(0x1af)]),_0x443670=document[_0x2776d0(0x398)](_0x2ef577['jyfsH']),_0xc118d0=_0x5298d2[_0x2776d0(0x2da)];if(_0xc118d0){_0x480d11[_0x2776d0(0x35b)]['remove'](_0x2ef577[_0x2776d0(0x42d)]);if(_0xc118d0[_0x2776d0(0x3cf)](_0x2ef577['CTSCc']))_0x2ef577['yDmYm'](setupVideo,_0x443670,_0xc118d0);else _0x443670[_0x2776d0(0x1e2)]=_0xc118d0;}else _0x2ef577[_0x2776d0(0x428)](_0x2ef577[_0x2776d0(0x3ff)],'zPKlp')?_0x480d11[_0x2776d0(0x35b)][_0x2776d0(0x3c6)](_0x2ef577[_0x2776d0(0x42d)]):_0x58d774();const _0xce7244=document[_0x2776d0(0x398)](_0x2ef577[_0x2776d0(0x400)]);_0xce7244['innerHTML']='';_0x5298d2[_0x2776d0(0x2ab)]&&(_0xce7244[_0x2776d0(0x2a2)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22'+_0x5298d2['explanation_audio_eng']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>');_0x5298d2['explanation_audio_hin']&&(_0x2ef577[_0x2776d0(0x21b)](_0x2ef577['bNEdV'],_0x2ef577[_0x2776d0(0x358)])?_0xce7244['innerHTML']+=_0x2776d0(0x256)+_0x5298d2['explanation_audio_hin']+_0x2776d0(0x34a):_0x365bd4[_0x2776d0(0x257)][_0x2776d0(0x1dc)](_0x23fa51=>{const _0x54db51=_0x2776d0;if(_0x23fa51)_0x4599b0['innerHTML']+=_0x54db51(0x3ca)+_0x23fa51+_0x54db51(0x41f);}));const _0x43d135=document[_0x2776d0(0x398)](_0x2776d0(0x3f5));_0x43d135[_0x2776d0(0x2a2)]='',_0x5298d2[_0x2776d0(0x257)]&&_0x5298d2['explanation_images']['forEach'](_0xdd47be=>{const _0x82de53=_0x2776d0,_0x41c684={'rwLPb':_0x2ef577[_0x82de53(0x3b8)],'pcltq':_0x2ef577[_0x82de53(0x266)],'nkuvS':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','FtLov':_0x2ef577[_0x82de53(0x3c9)]};if('iaAFf'!==_0x2ef577[_0x82de53(0x1f1)]){const _0x533e9c=_0x1fdb38[_0x82de53(0x398)](_0x41c684['rwLPb']),_0x393056=_0x5a2c66[_0x82de53(0x398)](_0x82de53(0x292)),_0x221988=_0x153ce7[_0x2d3eb2][_0x82de53(0x1a3)];_0x533e9c[_0x82de53(0x3e7)]=_0x221988?_0x41c684[_0x82de53(0x2b9)]:_0x41c684[_0x82de53(0x394)],_0x393056['textContent']=_0x221988?_0x82de53(0x3d8):_0x41c684[_0x82de53(0x2d6)];}else{if(_0xdd47be)_0x43d135[_0x82de53(0x2a2)]+=_0x82de53(0x3ca)+_0xdd47be+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}}),document[_0x2776d0(0x398)](_0x2776d0(0x362))[_0x2776d0(0x35b)]['remove'](_0x2ef577[_0x2776d0(0x42d)]);}function submitQuiz(){const _0x194f21=_0x2370d7,_0x4c28a0={'DRoKR':_0x194f21(0x2fb),'kQehg':_0x194f21(0x34d),'TdhYH':'.m3u8','WaoTE':function(_0x5b6739,_0x1c2c40,_0x5a51a0){return _0x5b6739(_0x1c2c40,_0x5a51a0);},'sPadP':function(_0x13d271,_0x53ecb9){return _0x13d271!==_0x53ecb9;},'uZAAI':'ZCdxv','jXrAl':_0x194f21(0x396),'mfNNQ':'IaeyO','ySPbo':function(_0x226868,_0x1a0889){return _0x226868===_0x1a0889;},'LTNNj':'QWwdO','sThlK':_0x194f21(0x232),'ZfWiP':function(_0x1ed522,_0x2270ec){return _0x1ed522!==_0x2270ec;},'hokci':_0x194f21(0x3d4),'Bfipo':_0x194f21(0x209),'Iaqbj':function(_0x594d86,_0x330ece){return _0x594d86(_0x330ece);},'UWvyw':function(_0x54d0e0,_0x19fcc4){return _0x54d0e0(_0x19fcc4);},'TrUsf':_0x194f21(0x383),'eVGxK':function(_0x2d2801,_0x58eaf5){return _0x2d2801-_0x58eaf5;},'vKLvF':function(_0x46305e,_0x50943d){return _0x46305e+_0x50943d;},'VBwpa':function(_0x29b6e2){return _0x29b6e2();},'kaXVp':function(_0x33a8bf,_0x421628,_0x5adf7f,_0x3b07b9,_0x5e812f){return _0x33a8bf(_0x421628,_0x5adf7f,_0x3b07b9,_0x5e812f);},'rnUrV':function(_0x663746,_0x412e58){return _0x663746+_0x412e58;}};if(timer)_0x4c28a0[_0x194f21(0x1c1)](clearInterval,timer);if(!_0x4c28a0['UWvyw'](confirm,_0x194f21(0x395)))return;isQuizCompleted=!![];let _0x5599b9=0x0,_0x105048=0x0;const _0x2b8ba3=Date[_0x194f21(0x2b3)]()-quizStartTime;questionsData[_0x194f21(0x1dc)]((_0x156811,_0x19b757)=>{const _0x386ede=_0x194f21,_0x4d130c={'zqpGX':_0x4c28a0[_0x386ede(0x293)],'MpnPB':function(_0x3dc26d,_0x58f3e6,_0x1c28c3){const _0x22f9e4=_0x386ede;return _0x4c28a0[_0x22f9e4(0x357)](_0x3dc26d,_0x58f3e6,_0x1c28c3);}};if(_0x4c28a0[_0x386ede(0x1ff)](_0x386ede(0x1b6),_0x4c28a0['uZAAI'])){const _0x542deb=questionStates[_0x19b757];_0x542deb[_0x386ede(0x313)]!==null&&(_0x4c28a0[_0x386ede(0x1ff)](_0x4c28a0[_0x386ede(0x218)],_0x4c28a0[_0x386ede(0x290)])?_0x4c28a0[_0x386ede(0x295)](_0x156811[_0x386ede(0x1da)][_0x542deb[_0x386ede(0x313)]]['id'],_0x156811[_0x386ede(0x28d)])?_0x4c28a0[_0x386ede(0x1ff)]('QWwdO',_0x4c28a0[_0x386ede(0x311)])?_0x25fbe9=_0x16c74b:(_0x5599b9++,_0x542deb[_0x386ede(0x2d2)]=_0x4c28a0['sThlK']):_0x4c28a0[_0x386ede(0x36b)]('qecAD',_0x4c28a0[_0x386ede(0x2ed)])?_0x2209f1():(_0x105048++,_0x542deb[_0x386ede(0x2d2)]=_0x4c28a0[_0x386ede(0x305)]):_0x14ba61[_0x386ede(0x398)](_0x4c28a0[_0x386ede(0x220)])[_0x386ede(0x35b)]['remove'](_0x4c28a0[_0x386ede(0x249)]));}else{const _0x224cb1=_0x30c587[_0x386ede(0x31b)]['src'];if(_0x224cb1&&_0x224cb1[_0x386ede(0x3cf)](_0x4d130c['zqpGX']))_0x4d130c[_0x386ede(0x1d1)](_0x5c59eb,_0xe89872,_0x224cb1);else _0x224cb1&&(_0x11e314['src']=_0x224cb1);}});const _0x3af46f=JSON[_0x194f21(0x267)](localStorage[_0x194f21(0x2cd)](_0x4c28a0['TrUsf']))||[];_0x3af46f[_0x194f21(0x332)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x194f21(0x2b3)](),'totalTime':_0x2b8ba3,'stats':{'correct':_0x5599b9,'incorrect':_0x105048,'notAttempted':_0x4c28a0[_0x194f21(0x2de)](questionsData[_0x194f21(0x1cd)],_0x4c28a0['vKLvF'](_0x5599b9,_0x105048))}}),localStorage['setItem'](_0x4c28a0[_0x194f21(0x2fd)],JSON[_0x194f21(0x297)](_0x3af46f)),stats[_0x194f21(0x385)]=_0x5599b9,stats[_0x194f21(0x3c2)]=_0x105048,_0x4c28a0['VBwpa'](markQuizAsCompleted),_0x4c28a0['kaXVp'](showPerformanceAnalysis,_0x5599b9,_0x105048,_0x4c28a0[_0x194f21(0x2de)](questionsData[_0x194f21(0x1cd)],_0x4c28a0[_0x194f21(0x361)](_0x5599b9,_0x105048)),_0x2b8ba3);}function showPerformanceAnalysis(_0x1caf01,_0x313bd9,_0x538577,_0x1cfd87){const _0x53d3b3=_0x2370d7,_0x4729e4={'ssheg':_0x53d3b3(0x420),'uKNal':function(_0x537865,_0x4d9aa7){return _0x537865>_0x4d9aa7;},'IYuIn':function(_0x106d13,_0x153b98){return _0x106d13*_0x153b98;},'nrOQJ':function(_0x13ab64,_0x9f8b3a){return _0x13ab64/_0x9f8b3a;},'tUzuQ':function(_0x19cd34,_0x51ec48){return _0x19cd34+_0x51ec48;},'fIVPD':_0x53d3b3(0x41c),'QAYjv':function(_0x19bff7,_0xd3c75d){return _0x19bff7-_0xd3c75d;},'tRqri':_0x53d3b3(0x2b7),'hnmaV':_0x53d3b3(0x298),'IenWI':_0x53d3b3(0x347),'yxAop':function(_0x53b31b,_0x49364c){return _0x53b31b/_0x49364c;},'ENeKd':function(_0x2203a0,_0x539a81){return _0x2203a0%_0x539a81;},'DSooS':_0x53d3b3(0x2ac)},_0x3ef05c=document[_0x53d3b3(0x398)](_0x4729e4[_0x53d3b3(0x1ee)]),_0x9771aa=_0x4729e4['uKNal'](_0x1caf01+_0x313bd9,0x0)?Math[_0x53d3b3(0x1db)](_0x4729e4[_0x53d3b3(0x3fd)](_0x4729e4['nrOQJ'](_0x1caf01,_0x4729e4[_0x53d3b3(0x20e)](_0x1caf01,_0x313bd9)),0x64)):0x0,_0x1b4ed1=_0x4729e4[_0x53d3b3(0x3fd)](_0x4729e4[_0x53d3b3(0x3fd)](0x2,Math['PI']),0x41),_0x5e7576=document[_0x53d3b3(0x398)](_0x4729e4[_0x53d3b3(0x1e3)]);_0x5e7576['style'][_0x53d3b3(0x356)]=_0x1b4ed1+'\x20'+_0x1b4ed1,_0x5e7576[_0x53d3b3(0x3c1)][_0x53d3b3(0x2d0)]=_0x4729e4[_0x53d3b3(0x392)](_0x1b4ed1,_0x4729e4[_0x53d3b3(0x3e6)](_0x9771aa,0x64)*_0x1b4ed1),document[_0x53d3b3(0x398)](_0x4729e4[_0x53d3b3(0x2bb)])[_0x53d3b3(0x224)]=_0x9771aa+'%',document[_0x53d3b3(0x398)]('totalQuestionsResult')['textContent']=questionsData[_0x53d3b3(0x1cd)],document[_0x53d3b3(0x398)](_0x53d3b3(0x2cc))[_0x53d3b3(0x224)]=_0x1caf01,document[_0x53d3b3(0x398)](_0x4729e4[_0x53d3b3(0x393)])[_0x53d3b3(0x224)]=_0x313bd9,document['getElementById'](_0x4729e4[_0x53d3b3(0x22b)])[_0x53d3b3(0x224)]=_0x538577;const _0x3b08ec=Math['floor'](_0x4729e4[_0x53d3b3(0x42e)](_0x1cfd87,0xea60)),_0x40ab7a=Math['floor'](_0x4729e4[_0x53d3b3(0x3b6)](_0x1cfd87,0xea60)/0x3e8);document['getElementById'](_0x4729e4[_0x53d3b3(0x29f)])['textContent']=_0x3b08ec+':'+_0x40ab7a[_0x53d3b3(0x2dd)]()[_0x53d3b3(0x1d2)](0x2,'0');const _0x200b23=_0x4729e4['yxAop'](_0x1cfd87,questionsData[_0x53d3b3(0x1cd)]),_0x3722ad=Math['floor'](_0x4729e4[_0x53d3b3(0x42e)](_0x200b23,0xea60)),_0x1397d0=Math[_0x53d3b3(0x399)](_0x4729e4[_0x53d3b3(0x42e)](_0x4729e4[_0x53d3b3(0x3b6)](_0x200b23,0xea60),0x3e8));document[_0x53d3b3(0x398)](_0x53d3b3(0x2c9))[_0x53d3b3(0x224)]=_0x3722ad+':'+_0x1397d0['toString']()[_0x53d3b3(0x1d2)](0x2,'0'),_0x3ef05c['classList']['remove']('hidden');}function closePerformanceModal(){const _0x3e222c=_0x2370d7,_0x536263={'iseDD':_0x3e222c(0x420),'Clnyi':_0x3e222c(0x34d)};document[_0x3e222c(0x398)](_0x536263[_0x3e222c(0x2e9)])['classList'][_0x3e222c(0x3c6)](_0x536263[_0x3e222c(0x417)]);}function reviewQuestions(){const _0x10c8c1=_0x2370d7,_0x133777={'ETsXZ':function(_0xe6b1d5,_0x550287){return _0xe6b1d5===_0x550287;},'SbrGe':_0x10c8c1(0x2ea),'IhDuv':_0x10c8c1(0x34e),'lsXzr':function(_0x7f4681,_0x53c8a7){return _0x7f4681===_0x53c8a7;},'zvUVg':_0x10c8c1(0x2f3),'npWwr':_0x10c8c1(0x200),'YHfTX':_0x10c8c1(0x325),'WJOKq':_0x10c8c1(0x3a4),'LpnzT':_0x10c8c1(0x317),'tFMMx':_0x10c8c1(0x232),'XDLoV':_0x10c8c1(0x343),'wMqzH':function(_0x4da206,_0x308226){return _0x4da206===_0x308226;},'TzJHE':_0x10c8c1(0x1ba),'ngOyj':_0x10c8c1(0x3b0),'iBpNx':'hidden','aKjFz':_0x10c8c1(0x1b3),'AmqQN':function(_0x95bbd0){return _0x95bbd0();}};document[_0x10c8c1(0x398)](_0x10c8c1(0x203))[_0x10c8c1(0x35b)][_0x10c8c1(0x320)](_0x133777[_0x10c8c1(0x1f9)]);const _0xde0010=document[_0x10c8c1(0x398)](_0x133777[_0x10c8c1(0x1f4)]);_0xde0010[_0x10c8c1(0x2a2)]='',questionsData['forEach']((_0x126926,_0x9d6c00)=>{const _0x1c740a=_0x10c8c1,_0x1f662a=questionStates[_0x9d6c00],_0x3f6266=_0x126926[_0x1c740a(0x28d)];let _0x1792b6=_0x1c740a(0x2ae),_0x562f4d=_0x133777[_0x1c740a(0x3f3)];if(_0x1f662a['selectedAnswer']!==null){const _0x641e99=_0x126926['choices'][_0x1f662a[_0x1c740a(0x313)]];_0x133777['ETsXZ'](_0x641e99['id'],_0x3f6266)?_0x133777[_0x1c740a(0x351)](_0x133777['zvUVg'],_0x133777[_0x1c740a(0x40e)])?_0x2c398d[_0x229ed6][_0x1c740a(0x422)]+=_0xe3a6e4[_0x1c740a(0x2b3)]()-_0x4e1537:(_0x1792b6=_0x1c740a(0x232),_0x562f4d=_0x133777[_0x1c740a(0x2b2)]):_0x1c740a(0x3a4)===_0x133777[_0x1c740a(0x1f2)]?(_0x1792b6='incorrect',_0x562f4d='Incorrect'):_0x5377d5['innerHTML']+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22'+_0x592d17[_0x1c740a(0x2ab)]+_0x1c740a(0x34a);}const _0x4c2dd9=document[_0x1c740a(0x3a0)](_0x133777[_0x1c740a(0x210)]);_0x4c2dd9[_0x1c740a(0x3e7)]=_0x1c740a(0x24e)+_0x1792b6;let _0x456a07=(_0x126926[_0x1c740a(0x1da)]||[])[_0x1c740a(0x3e5)]((_0x4ff60a,_0x3a05b5)=>{const _0x3dfcb9=_0x1c740a,_0x4146bf=_0x133777[_0x3dfcb9(0x411)](_0x1f662a[_0x3dfcb9(0x313)],_0x3a05b5),_0x2ecbd8=_0x4ff60a['id']===_0x3f6266;let _0x1a98b0=_0x133777[_0x3dfcb9(0x25c)];if(_0x2ecbd8)_0x1a98b0=_0x3dfcb9(0x353);else{if(_0x4146bf)_0x1a98b0=_0x3dfcb9(0x3a9);}return _0x3dfcb9(0x283)+_0x1a98b0+'\x22><span\x20class=\x22font-bold\x20mr-3\x22>'+String[_0x3dfcb9(0x401)](0x41+_0x3a05b5)+_0x3dfcb9(0x423)+_0x4ff60a[_0x3dfcb9(0x35c)]+_0x3dfcb9(0x1fe);})['join']('');const _0x3daeff=_0x126926[_0x1c740a(0x2da)]?_0x1c740a(0x388)+_0x9d6c00+_0x1c740a(0x1ea)+_0x126926['explanation_video']+'\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>':'';let _0x35e1c4='';if(_0x126926[_0x1c740a(0x2ab)])_0x35e1c4+=_0x1c740a(0x39b)+_0x126926[_0x1c740a(0x2ab)]+_0x1c740a(0x34a);if(_0x126926[_0x1c740a(0x321)])_0x35e1c4+=_0x1c740a(0x3b3)+_0x126926['explanation_audio_hin']+_0x1c740a(0x34a);let _0x55431c=(_0x126926[_0x1c740a(0x257)]||[])[_0x1c740a(0x3e5)](_0x45eb15=>_0x45eb15?_0x1c740a(0x3ca)+_0x45eb15+_0x1c740a(0x41f):'')['join']('');_0x4c2dd9[_0x1c740a(0x2a2)]=_0x1c740a(0x20f)+(_0x9d6c00+0x1)+_0x1c740a(0x2f6)+(_0x133777[_0x1c740a(0x351)](_0x1792b6,_0x133777[_0x1c740a(0x25e)])?_0x133777[_0x1c740a(0x40d)]:_0x133777[_0x1c740a(0x37a)](_0x1792b6,'incorrect')?'red':_0x133777[_0x1c740a(0x29e)])+_0x1c740a(0x258)+_0x562f4d+_0x1c740a(0x3d1)+_0x126926[_0x1c740a(0x35c)]+_0x1c740a(0x405)+_0x456a07+_0x1c740a(0x3e3)+(_0x126926[_0x1c740a(0x268)]||_0x133777[_0x1c740a(0x281)])+_0x1c740a(0x2f1)+_0x3daeff+_0x1c740a(0x2a6)+_0x35e1c4+_0x1c740a(0x2a6)+_0x55431c+'\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>',_0xde0010[_0x1c740a(0x41a)](_0x4c2dd9);}),_0x133777[_0x10c8c1(0x41b)](initializeReviewVideos);}function initializeReviewVideos(){const _0xd87549=_0x2370d7,_0x200667={'etnXi':function(_0x2d1dcb,_0x4b87a8){return _0x2d1dcb>_0x4b87a8;},'jIngH':function(_0x541f18,_0x4a9f73){return _0x541f18-_0x4a9f73;},'ecwkN':function(_0x332387){return _0x332387();},'ZvdhM':function(_0x31e1a7,_0x302335){return _0x31e1a7===_0x302335;},'mkRYR':_0xd87549(0x374),'aPaDS':_0xd87549(0x29d),'qKKhJ':_0xd87549(0x27b),'kOJHR':function(_0x2d1260,_0x440fb9){return _0x2d1260!==_0x440fb9;},'UZoCq':_0xd87549(0x42f),'GtOOP':function(_0x44c284,_0x2b8ed5,_0x56c4d4){return _0x44c284(_0x2b8ed5,_0x56c4d4);},'xVCkl':_0xd87549(0x260)};document['querySelectorAll'](_0x200667[_0xd87549(0x384)])['forEach'](_0x4dac04=>{const _0x1e6fa4=_0xd87549,_0x18fd85={'SoMvH':function(_0x3407d6,_0x50c115){return _0x200667['etnXi'](_0x3407d6,_0x50c115);},'oQIzB':function(_0x53b0c5,_0x36f95a){const _0x2297d3=_0x407a;return _0x200667[_0x2297d3(0x3d0)](_0x53b0c5,_0x36f95a);},'lFFRZ':function(_0x402a57){const _0x233fd8=_0x407a;return _0x200667[_0x233fd8(0x319)](_0x402a57);}};if(_0x200667['ZvdhM'](_0x200667[_0x1e6fa4(0x3fc)],_0x200667[_0x1e6fa4(0x225)]))_0x267643=_0x2dcb51[_0x1e6fa4(0x306)](_0xeb4112=>!(_0xeb4112[_0x1e6fa4(0x2bd)][_0x1e6fa4(0x3cf)](_0x3effcb['toLowerCase']()[_0x1e6fa4(0x280)](/ /g,'-'))&&_0xeb4112[_0x1e6fa4(0x2c5)]===_0x5da271));else{const _0x2cf0b3=_0x4dac04[_0x1e6fa4(0x31b)][_0x1e6fa4(0x1e2)];if(_0x2cf0b3&&_0x2cf0b3[_0x1e6fa4(0x3cf)](_0x200667[_0x1e6fa4(0x3a1)]))_0x200667['kOJHR'](_0x200667[_0x1e6fa4(0x228)],_0x1e6fa4(0x223))?_0x200667[_0x1e6fa4(0x276)](setupVideo,_0x4dac04,_0x2cf0b3):_0x18fd85[_0x1e6fa4(0x294)](_0x3b0483,0x0)&&(_0x43e770&&(_0x17abfb[_0x4689ff][_0x1e6fa4(0x422)]+=_0x18fd85['oQIzB'](_0xb96529[_0x1e6fa4(0x2b3)](),_0x12a22a)),_0xf5679e--,_0x18fd85[_0x1e6fa4(0x2cf)](_0x1ec689),_0x18fd85[_0x1e6fa4(0x2cf)](_0x17df08));else _0x2cf0b3&&(_0x4dac04[_0x1e6fa4(0x1e2)]=_0x2cf0b3);}});}function retakeQuiz(){const _0x2cfad1=_0x2370d7,_0x3348d4={'sNquu':function(_0x5ddc85,_0x40e6a7){return _0x5ddc85(_0x40e6a7);},'ecLwu':'Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','byQCi':function(_0x281b66){return _0x281b66();}};_0x3348d4[_0x2cfad1(0x201)](confirm,_0x3348d4[_0x2cfad1(0x3ee)])&&(window[_0x2cfad1(0x3bb)][_0x2cfad1(0x382)][_0x2cfad1(0x2b6)](_0x2cfad1(0x41e))&&localStorage['removeItem'](_0x2cfad1(0x2e1)),_0x3348d4[_0x2cfad1(0x3bf)](clearProgress),location[_0x2cfad1(0x3f1)]());}function loadBookmarkedQuestions(){const _0x54faf4=_0x2370d7,_0x3cd35c={'efUIy':function(_0x55c0b1,_0x2dbd0e){return _0x55c0b1-_0x2dbd0e;},'GGMBJ':function(_0xe011ef){return _0xe011ef();},'BNQDD':function(_0x56e8cb,_0x162d77){return _0x56e8cb!==_0x162d77;},'GEshe':'GsXfg','SeVmI':_0x54faf4(0x3f4),'vWBRS':'bookmarkedQuestions'},_0x48223e=JSON[_0x54faf4(0x267)](localStorage[_0x54faf4(0x2cd)](_0x3cd35c[_0x54faf4(0x30f)]))||[];_0x48223e[_0x54faf4(0x1dc)](_0x443f3f=>{const _0x6b9aa0=_0x54faf4;_0x3cd35c[_0x6b9aa0(0x32b)](_0x3cd35c[_0x6b9aa0(0x37e)],_0x3cd35c[_0x6b9aa0(0x1b4)])?_0x443f3f[_0x6b9aa0(0x2bd)][_0x6b9aa0(0x3cf)](quizName[_0x6b9aa0(0x21e)]()['replace'](/ /g,'-'))&&(_0x443f3f[_0x6b9aa0(0x2c5)]<questionsData[_0x6b9aa0(0x1cd)]&&(questionStates[_0x443f3f[_0x6b9aa0(0x2c5)]][_0x6b9aa0(0x1a3)]=!![])):(_0x2fc627&&(_0x545de8[_0x275700]['timeSpent']+=_0x3cd35c['efUIy'](_0x582abc[_0x6b9aa0(0x2b3)](),_0x6db056)),_0x52215c=_0x444efb,_0x3cd35c['GGMBJ'](_0x1a661b),_0x3cd35c[_0x6b9aa0(0x235)](_0x3a2814));});}function toggleBookmark(){const _0x22ce6f=_0x2370d7,_0x4e3fd9={'EjykS':function(_0x1c63f1,_0x14de88){return _0x1c63f1>=_0x14de88;},'aMmth':function(_0x1ce5c4,_0x58e146){return _0x1ce5c4<_0x58e146;},'ylTfP':function(_0x1143db,_0x50fb7f){return _0x1143db-_0x50fb7f;},'ItzRh':function(_0x15d64b){return _0x15d64b();},'VrdBj':_0x22ce6f(0x3d7),'DxzVe':function(_0x28a647,_0x5d0a0e){return _0x28a647!==_0x5d0a0e;},'yOppm':function(_0x1d1915,_0x4dc9ab){return _0x1d1915===_0x4dc9ab;},'YMoTX':_0x22ce6f(0x21d),'gggGr':_0x22ce6f(0x3ea)},_0x13acc1=!questionStates[currentQuestionIndex][_0x22ce6f(0x1a3)];questionStates[currentQuestionIndex]['bookmarked']=_0x13acc1;let _0x508257=JSON[_0x22ce6f(0x267)](localStorage[_0x22ce6f(0x2cd)](_0x4e3fd9['VrdBj']))||[];if(_0x13acc1){if(_0x4e3fd9[_0x22ce6f(0x37f)](_0x22ce6f(0x28a),'JXVKQ'))_0x4e3fd9['EjykS'](_0x24e1c3,0x0)&&_0x4e3fd9['aMmth'](_0x509cb5,_0xf5743['length'])&&(_0x372fab&&(_0x142cf9[_0x137740][_0x22ce6f(0x422)]+=_0x4e3fd9[_0x22ce6f(0x2d9)](_0x39343d[_0x22ce6f(0x2b3)](),_0x4f230e)),_0x13ca7f=_0xe274a1,_0x4e3fd9['ItzRh'](_0x20fc30),_0x4e3fd9[_0x22ce6f(0x3d2)](_0x27e07f));else{const _0x5d6704={'quizName':quizName,'quizFile':window['location']['pathname'][_0x22ce6f(0x1e6)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date['now']()};_0x508257[_0x22ce6f(0x332)](_0x5d6704);}}else _0x4e3fd9[_0x22ce6f(0x2b1)](_0x4e3fd9['YMoTX'],_0x4e3fd9[_0x22ce6f(0x32c)])?_0x3393c7=_0x22ce6f(0x327):_0x508257=_0x508257['filter'](_0x189c99=>!(_0x189c99[_0x22ce6f(0x2bd)][_0x22ce6f(0x3cf)](quizName[_0x22ce6f(0x21e)]()[_0x22ce6f(0x280)](/ /g,'-'))&&_0x189c99[_0x22ce6f(0x2c5)]===currentQuestionIndex));localStorage[_0x22ce6f(0x34f)](_0x4e3fd9['VrdBj'],JSON['stringify'](_0x508257)),updateBookmarkButton(),_0x4e3fd9['ItzRh'](updateQuestionNav);}function updateBookmarkButton(){const _0x20ea4e=_0x2370d7,_0x3f7d07={'ZvYNs':'bookmarkBtn','bPOsj':_0x20ea4e(0x292),'uWApG':_0x20ea4e(0x259),'IFJHe':'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','tPqsu':_0x20ea4e(0x3d8),'RcXuJ':_0x20ea4e(0x1ce)},_0x49ed82=document[_0x20ea4e(0x398)](_0x3f7d07[_0x20ea4e(0x39f)]),_0x5a47fc=document[_0x20ea4e(0x398)](_0x3f7d07['bPOsj']),_0xc39dd7=questionStates[currentQuestionIndex][_0x20ea4e(0x1a3)];_0x49ed82[_0x20ea4e(0x3e7)]=_0xc39dd7?_0x3f7d07[_0x20ea4e(0x377)]:_0x3f7d07[_0x20ea4e(0x1f7)],_0x5a47fc[_0x20ea4e(0x224)]=_0xc39dd7?_0x3f7d07[_0x20ea4e(0x40b)]:_0x3f7d07['RcXuJ'];}function toggleMarkForReview(){const _0x4d40d3=_0x2370d7,_0x2d7b19={'xJANK':function(_0x22efa6){return _0x22efa6();}};questionStates[currentQuestionIndex][_0x4d40d3(0x27e)]=!questionStates[currentQuestionIndex][_0x4d40d3(0x27e)],updateMarkReviewButton(),_0x2d7b19[_0x4d40d3(0x3fe)](updateQuestionNav);}function updateMarkReviewButton(){const _0x19818e=_0x2370d7,_0x10be23={'bKZhs':_0x19818e(0x301),'pLYAb':_0x19818e(0x2ca),'JEqhs':_0x19818e(0x241),'KFsgb':_0x19818e(0x3b9),'SOZwY':_0x19818e(0x2ec)},_0x50d105=document[_0x19818e(0x398)](_0x10be23[_0x19818e(0x3cb)]),_0x794333=document[_0x19818e(0x398)](_0x19818e(0x36a)),_0x5224bc=questionStates[currentQuestionIndex][_0x19818e(0x27e)];_0x50d105[_0x19818e(0x3e7)]=_0x5224bc?_0x10be23[_0x19818e(0x419)]:_0x10be23[_0x19818e(0x1e4)],_0x794333[_0x19818e(0x224)]=_0x5224bc?_0x10be23[_0x19818e(0x425)]:_0x10be23[_0x19818e(0x240)];}function previousQuestion(){const _0x3f8b20=_0x2370d7,_0x322e78={'epuOc':function(_0x51056e,_0x4bc3b7){return _0x51056e>_0x4bc3b7;},'JgSoc':function(_0x1b8802,_0x326b7b){return _0x1b8802-_0x326b7b;}};_0x322e78['epuOc'](currentQuestionIndex,0x0)&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x3f8b20(0x422)]+=_0x322e78[_0x3f8b20(0x318)](Date[_0x3f8b20(0x2b3)](),questionStartTime)),currentQuestionIndex--,displayQuestion(),saveProgress());}function nextQuestion(){const _0x50d802=_0x2370d7,_0x4986a4={'cVFKr':function(_0x113b4a,_0x116249){return _0x113b4a-_0x116249;},'nvCJP':function(_0x3c0c24,_0x5f5709){return _0x3c0c24<_0x5f5709;},'oVEPh':function(_0xd2c00,_0x791c98){return _0xd2c00-_0x791c98;},'FrHsh':function(_0x3bc8be){return _0x3bc8be();},'Xnglt':function(_0x324d9d,_0x456aea){return _0x324d9d!==_0x456aea;},'KLiNr':_0x50d802(0x2a8),'QbRHO':_0x50d802(0x23a),'SowGb':function(_0x1a4b4d,_0x3ffc05){return _0x1a4b4d===_0x3ffc05;},'ujiAB':'test','FxZJK':function(_0x23d5e0,_0x2d5e54){return _0x23d5e0===_0x2d5e54;},'wFdOn':_0x50d802(0x408),'PHoVf':function(_0x43202a,_0x1b14f8){return _0x43202a(_0x1b14f8);},'LIiEg':_0x50d802(0x28e),'ApgmE':function(_0x2c5ce8,_0x58e921){return _0x2c5ce8!==_0x58e921;},'cqspy':'XTJlS','ZmVcE':_0x50d802(0x2a5),'XpTZM':function(_0x2dfefa){return _0x2dfefa();}};questionStartTime&&(questionStates[currentQuestionIndex]['timeSpent']+=_0x4986a4[_0x50d802(0x26f)](Date[_0x50d802(0x2b3)](),questionStartTime)),_0x4986a4[_0x50d802(0x284)](currentQuestionIndex,_0x4986a4[_0x50d802(0x308)](questionsData['length'],0x1))?(currentQuestionIndex++,_0x4986a4['FrHsh'](displayQuestion),_0x4986a4['FrHsh'](saveProgress)):_0x4986a4['Xnglt'](_0x4986a4[_0x50d802(0x234)],_0x4986a4[_0x50d802(0x269)])?_0x4986a4[_0x50d802(0x2d4)](currentMode,_0x4986a4[_0x50d802(0x237)])||_0x4986a4[_0x50d802(0x3c4)](currentMode,_0x4986a4[_0x50d802(0x1c4)])?_0x4986a4[_0x50d802(0x1a9)](confirm,_0x4986a4[_0x50d802(0x37d)])&&(_0x4986a4[_0x50d802(0x1f0)]('XTJlS',_0x4986a4[_0x50d802(0x29c)])?_0x3fef38['src']=_0x51123c:submitQuiz()):_0x4986a4['PHoVf'](confirm,_0x4986a4['ZmVcE'])&&(currentQuestionIndex=0x0,_0x4986a4[_0x50d802(0x407)](displayQuestion),_0x4986a4['XpTZM'](saveProgress)):_0x2e561c[_0x50d802(0x2a2)]+='<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22'+_0x547021[_0x50d802(0x321)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';}function startTimer(){const _0x33efad=_0x2370d7,_0x388fb1={'iGCVG':function(_0x29a00e){return _0x29a00e();},'bXyfi':function(_0x38d8a7){return _0x38d8a7();},'PJHwK':function(_0x13b898,_0x40a5a1){return _0x13b898===_0x40a5a1;},'kRSUO':_0x33efad(0x222),'YXDnM':function(_0x37d550,_0x13c122){return _0x37d550(_0x13c122);},'DRpMq':'timed_exam','bbSTw':_0x33efad(0x19e),'vSAgC':function(_0x12f970,_0x25a368){return _0x12f970!==_0x25a368;},'LEYIw':'tmQUT','zeXOW':'cIXRn','lOKTO':function(_0x27026c,_0x364b45){return _0x27026c(_0x364b45);},'YHbyP':function(_0x4ec4ac,_0x4a2ef8,_0x476ca3){return _0x4ec4ac(_0x4a2ef8,_0x476ca3);}};if(timer)_0x388fb1['lOKTO'](clearInterval,timer);timeRemaining=0x78,_0x388fb1['bXyfi'](updateTimerDisplay),timer=_0x388fb1[_0x33efad(0x415)](setInterval,()=>{const _0x358d01=_0x33efad,_0x32f550={'LDdOB':function(_0x4cea82){const _0x23a8ce=_0x407a;return _0x388fb1[_0x23a8ce(0x1ae)](_0x4cea82);},'SCRsT':function(_0x2dfcc2){const _0x3dc494=_0x407a;return _0x388fb1[_0x3dc494(0x381)](_0x2dfcc2);}};if(_0x388fb1[_0x358d01(0x1c9)](_0x388fb1[_0x358d01(0x246)],_0x388fb1[_0x358d01(0x246)])){timeRemaining--,_0x388fb1[_0x358d01(0x1ae)](updateTimerDisplay);if(timeRemaining<=0x0){_0x388fb1[_0x358d01(0x365)](clearInterval,timer);if(currentMode===_0x388fb1['DRpMq'])_0x388fb1[_0x358d01(0x1c9)](_0x388fb1[_0x358d01(0x26a)],_0x358d01(0x286))?_0x37485c[_0x358d01(0x2c5)]<_0x185b27['length']&&(_0x4e1f5e[_0x256891[_0x358d01(0x2c5)]][_0x358d01(0x1a3)]=!![]):_0x388fb1[_0x358d01(0x1ae)](submitQuiz);else{if(_0x388fb1[_0x358d01(0x344)](_0x388fb1[_0x358d01(0x1e0)],_0x388fb1[_0x358d01(0x33d)]))_0x388fb1[_0x358d01(0x1ae)](nextQuestion);else{const _0x2993df=_0x23c219['apply'](_0x38b5e2,arguments);return _0x53b39b=null,_0x2993df;}}}}else _0xeacb3=0x0,_0x32f550[_0x358d01(0x23c)](_0x1d7b1b),_0x32f550[_0x358d01(0x3ab)](_0x3e802a);},0x3e8);}function updateTimerDisplay(){const _0x11105b=_0x2370d7,_0x919b3b={'ykBRX':function(_0x11fdd9,_0x55d362){return _0x11fdd9/_0x55d362;},'YZOYh':function(_0x545093,_0x19fcce){return _0x545093%_0x19fcce;},'Atgvd':function(_0x5afcc0,_0x12cc7c){return _0x5afcc0+_0x12cc7c;}},_0x3ee52f=Math[_0x11105b(0x399)](_0x919b3b[_0x11105b(0x40c)](timeRemaining,0x3c)),_0x1ecffe=_0x919b3b[_0x11105b(0x367)](timeRemaining,0x3c);document[_0x11105b(0x398)](_0x11105b(0x2c3))['textContent']=_0x919b3b['Atgvd'](_0x3ee52f,':')+_0x1ecffe[_0x11105b(0x2dd)]()[_0x11105b(0x1d2)](0x2,'0');}function toggleSidebar(){const _0x31ec84=_0x2370d7,_0x2736f4={'yshjd':_0x31ec84(0x429),'hqslC':_0x31ec84(0x2ee)};document['getElementById'](_0x2736f4['yshjd'])[_0x31ec84(0x35b)]['toggle'](_0x2736f4[_0x31ec84(0x397)]);}document[_0x2370d7(0x369)]('DOMContentLoaded',()=>{const _0x4176a5=_0x2370d7,_0xcf6ac1={'rlEEF':function(_0x6931b7){return _0x6931b7();},'HglZN':'Ettmy','Ptyht':_0x4176a5(0x30e),'ZLbkc':_0x4176a5(0x41e),'ghiKn':'flex'};if(resume)loadProgress()?_0xcf6ac1[_0x4176a5(0x299)]!==_0xcf6ac1['HglZN']?_0xcf6ac1['rlEEF'](_0x221195):(document[_0x4176a5(0x398)](_0x4176a5(0x30e))[_0x4176a5(0x3c1)][_0x4176a5(0x350)]=_0x4176a5(0x3a7),_0xcf6ac1['rlEEF'](initializeQuiz)):(_0xcf6ac1[_0x4176a5(0x2f0)](clearProgress),document['getElementById'](_0xcf6ac1[_0x4176a5(0x2ba)])['style'][_0x4176a5(0x350)]=_0x4176a5(0x217));else!window['location'][_0x4176a5(0x382)][_0x4176a5(0x2b6)](_0xcf6ac1['ZLbkc'])?(clearProgress(),document[_0x4176a5(0x398)](_0xcf6ac1['Ptyht'])[_0x4176a5(0x3c1)][_0x4176a5(0x350)]=_0xcf6ac1[_0x4176a5(0x2ce)]):initializeQuiz();}),document[_0x2370d7(0x369)](_0x2370d7(0x206),function(_0x10c46c){const _0x4ec474=_0x2370d7,_0x4b8377={'tmVbl':_0x4ec474(0x1ed),'paEAO':_0x4ec474(0x30e),'jScIp':_0x4ec474(0x3a7),'HgaJw':function(_0x2734ca,_0x2e93ea){return _0x2734ca===_0x2e93ea;},'UfBcJ':_0x4ec474(0x420),'pcWcT':_0x4ec474(0x34d),'raTKL':function(_0xed53f7,_0x2b0bcf){return _0xed53f7<=_0x2b0bcf;},'zqzrj':function(_0x3cb1be,_0x4870ec){return _0x3cb1be-_0x4870ec;},'RdpVa':function(_0x3dbba9,_0x2c61ec){return _0x3dbba9(_0x2c61ec);},'asZFF':_0x4ec474(0x3f0),'qIIlA':function(_0xfe2033){return _0xfe2033();},'BluPJ':_0x4ec474(0x363),'TpmfU':function(_0x2a1485){return _0x2a1485();},'JYVrt':function(_0x5ec796,_0x5a0055){return _0x5ec796===_0x5a0055;},'xIhNI':_0x4ec474(0x3c3),'OMjKg':_0x4ec474(0x251),'chPFp':_0x4ec474(0x1b1),'Jpbep':'OmKHt','fSVxL':function(_0xb53dce){return _0xb53dce();},'DVNuc':_0x4ec474(0x3f8),'WvugF':function(_0x2dbed3,_0x22dd91){return _0x2dbed3===_0x22dd91;},'CsXVq':_0x4ec474(0x408),'OFXAW':_0x4ec474(0x41d),'lECnU':function(_0x55a283){return _0x55a283();},'jxAhR':function(_0x13daa0,_0x40260f){return _0x13daa0===_0x40260f;}};if(document['getElementById'](_0x4b8377[_0x4ec474(0x33f)])[_0x4ec474(0x3c1)][_0x4ec474(0x350)]!==_0x4b8377[_0x4ec474(0x1c8)])return;if(_0x4b8377[_0x4ec474(0x1aa)](document[_0x4ec474(0x398)](_0x4b8377[_0x4ec474(0x380)])[_0x4ec474(0x35b)][_0x4ec474(0x244)](_0x4b8377[_0x4ec474(0x287)]),![]))return;if(_0x10c46c[_0x4ec474(0x303)]>='1'&&_0x4b8377[_0x4ec474(0x3fa)](_0x10c46c[_0x4ec474(0x303)],'4')){const _0x1b45f4=_0x4b8377[_0x4ec474(0x282)](_0x4b8377[_0x4ec474(0x239)](parseInt,_0x10c46c[_0x4ec474(0x303)]),0x1),_0x560ef6=document[_0x4ec474(0x3d5)](_0x4b8377[_0x4ec474(0x208)]);if(_0x1b45f4<_0x560ef6[_0x4ec474(0x1cd)])_0x4b8377[_0x4ec474(0x239)](selectOption,_0x1b45f4);}else{if(_0x4b8377[_0x4ec474(0x1aa)](_0x10c46c['key'],'ArrowLeft'))_0x4b8377['qIIlA'](previousQuestion);else{if(_0x4b8377[_0x4ec474(0x1aa)](_0x10c46c[_0x4ec474(0x303)],_0x4b8377['BluPJ'])||_0x4b8377['HgaJw'](_0x10c46c['key'],'\x20'))_0x10c46c['preventDefault'](),_0x4b8377[_0x4ec474(0x273)](nextQuestion);else{if(_0x4b8377[_0x4ec474(0x1aa)](_0x10c46c['key'][_0x4ec474(0x21e)](),'b')&&(_0x4b8377[_0x4ec474(0x247)](currentMode,_0x4b8377[_0x4ec474(0x2d3)])||currentMode===_0x4b8377[_0x4ec474(0x406)])){if(_0x4b8377[_0x4ec474(0x243)]!==_0x4b8377[_0x4ec474(0x3cc)])_0x4b8377[_0x4ec474(0x309)](toggleBookmark);else{const _0x26899c=_0x577d52['parse'](_0x1a9eea[_0x4ec474(0x2cd)](_0x4b8377[_0x4ec474(0x39c)]))||{},_0xdecf30=_0x26899c[_0x57349c];if(_0xdecf30)return _0x2e84c1=_0xdecf30['questionStates'],_0x55c455=_0xdecf30[_0x4ec474(0x328)],_0x2406dd=_0xdecf30[_0x4ec474(0x416)],_0x416142=_0xdecf30['currentMode'],_0xc162be[_0x4ec474(0x1d9)](_0x4ec474(0x212)),!![];return![];}}else{if(_0x4b8377[_0x4ec474(0x1aa)](_0x10c46c[_0x4ec474(0x303)][_0x4ec474(0x21e)](),'m')&&(currentMode===_0x4b8377['DVNuc']||_0x4b8377[_0x4ec474(0x389)](currentMode,_0x4b8377[_0x4ec474(0x307)]))){if('QNAUt'!==_0x4b8377[_0x4ec474(0x2e5)]){_0x5c31eb[_0x4ec474(0x341)]++,_0x3a61a4[_0x4ec474(0x279)]--;if(_0xa1b19d)_0x1cdfa0[_0x4ec474(0x385)]++;else _0x2c8638[_0x4ec474(0x3c2)]++;}else _0x4b8377[_0x4ec474(0x3d3)](toggleMarkForReview);}else _0x10c46c[_0x4ec474(0x303)][_0x4ec474(0x21e)]()==='s'&&(_0x4b8377[_0x4ec474(0x1e5)](currentMode,_0x4b8377['DVNuc'])||_0x4b8377['jxAhR'](currentMode,_0x4b8377[_0x4ec474(0x307)]))&&_0x4b8377[_0x4ec474(0x273)](submitQuiz);}}}}});</script>

</body></html>